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Neonatal abstinence syndrome (NAS) is a postnatal withdrawal syndrome among neonates 
born to drug-dependent mothers. NAS poses a significant health and fiscal challenge 
nationally, with its incidence increasing by a factor of six (1.20 to 6.7 per 1,000 hospital 
births/year) along with the concomitant rise in health care cost from 2000-2016. Besides 
national data, it is critical to quantify NAS at the state-level to identify the target areas for 
prevention. Given the higher opioid prescribing rates among pregnant women in Nevada, it is 
critical to assess the health and financial magnitude of NAS in the state. The objectives of 
this cross-sectional study were to describe the burden of NAS in Nevada from 2016 to 2018, 
including incidence, hospital utilization trends and cost, and differences across demographic 
and clinical characteristics between newborns with and without a NAS diagnosis. This study 
utilized hospital administrative data from the Center for Health Information Analysis. The 
units of observation were in-patient pediatric discharges with a diagnostic code of NAS 
following maternal drug abuse. Statistical analyses included estimation of crude incidence 
rates per 1,000 hospital births, bootstrapped significance testing for independent-samples t-
tests and chi-square tests, and multilevel logistic regression modelling. Results demonstrated 
an increase in overall NAS incidence of 8 per 1,000 hospital births, with disproportionate 
effects in certain demographic groups. The incidence of NAS was the highest among white 
newborns (12 per 1,000 hospital births) and those who were Medicaid insured (13.2 per 1,000 
hospital births). NAS infants were more likely to experience other clinical conditions, longer 
hospital stays (mean length of stay 17 days), incur higher health care costs, and undergo 
intense medical procedures. NAS has taken a heavy toll on Nevada’s health care system with 
over 75% of the total cost attributed to state Medicaid programs. These findings support the 
need for targeted interventions in clinical and public health settings aimed at prevention and 
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Chapter 1. Introduction 
Background   
Neonatal abstinence syndrome (NAS) is a constellation of withdrawal symptoms, 
manifested immediately after birth among babies of drug-dependent mothers, following 
abrupt discontinuation of in-utero exposure to the drugs, including prescription or illicit 
drugs (Hamdan, 2019; Hudak & Tan, 2012; Lisonkova et al., 2019; March of Dimes, 
2017). The risk of withdrawal syndrome may also exist for critically ill or hospitalized 
infants, who develop physical dependence on medications used for achieving analgesia and 
sedation (Hudak & Tan, 2012). The latter is called neonatal iatrogenic withdrawal, which 
occurs secondary to therapeutic exposure of the drugs used in the neonatal intensive care 
units (NICU) (Crampton & Gruchala, 2013; Hall & Shbarou, 2009; Hudak & Tan, 2012).  
The most common group of analgesics and sedatives used to treat chronic pain conditions 
in mothers and infants are opioids and benzodiazepines, including morphine, fentanyl, 
methadone, and midazolam (Hall & Shbarou, 2009). NAS and neonatal iatrogenic 
withdrawal present a similar spectrum of symptoms, affecting mainly the central nervous 
system, peripheral nervous system, and gastrointestinal system (Crampton & Gruchala, 
2013; Logan, Brown, & Hayes, 2013; Finnegan, Hagan, & Kaltenbach 1991). Symptoms 
include wakefulness, irritability (high-pitched cry), tremors, hypertonic muscles, diarrhea, 
regurgitation (poor sucking reflex), difficulty breathing, and impaired weight gain (Logan 
et al., 2013; March of Dimes, 2017; McQueen & Murphy-Oikonen, 2016).  The symptoms 
appear within the first few days after birth and are of variable severity (McQueen & 
Murphy-Oikonen, 2016). The severity of NAS symptoms can be assessed by the Modified 




Diagnosis: The Finnegan scoring system, which is also called the Neonatal Abstinence 
Scoring System (NASS), is a widely used diagnostic tool (Jones et al., 2016; McQueen & 
Murphy-Oikonen, 2016). The tool was further modified by the American Academy of 
Pediatrics (Hudak & Tan, 2012; McQueen & Murphy-Oikonen, 2016). This modified version 
(Appendix A.1) is a 30-item questionnaire with score ranges from 0 to 44; scores equal or 
greater than 8 are suggestive of NAS (Zimmermann-Baer, Nötzli, Rentsch, & Bucher, 2010). 
Other assessment tools include the Narcotic Withdrawal Score (Lipsitz score) and the 
Neonatal Narcotic Withdrawal Index (NWI) (Bagley, Wachman, Holland, & Brogly 2014; 
Jones et al., 2016). The newer ESC (Eat, Sleep, Console) approach has been reported to be an 
effective method of assessment to reduce the need of pharmacologic management with 
subsequent decrease in length of hospital stay (Grossman, Lipshaw, Osborn, & Berkwitt 
2017). The ESC approach identifies an infant not requiring further intervention if he or she 
eats at least 1 ounce per feed, has undisturbed sleep for an hour, and is consolable (if crying) 
within 10 minutes (Gross et al., 2017; Appendix A.2).  
Treatment: NAS can be managed by non-pharmacological and pharmacologic interventions 
(March of Dimes, 2017). The non-pharmacologic methods include rooming-in with the 
mother, skin to skin contact (Kangaroo care), avoiding overstimulation by having a calm 
environment, and encouraging breast feeding if not otherwise contraindicated (Bagley et al., 
2016; Hünseler, Brückle, Roth, & Kribs, 2013; March of Dimes, 2017).  In addition, bed 
type, positioning of the infant (Prone versus Supine), and non-insertive acupuncture (NIA) 
were reported to be useful adjuncts to supportive care of drug-exposed infants (Bagley et al., 
2016; D'Apolito, 1999; Filippelli et al., 2012; Maichuk, Zahorodny, & Marshall, 1999; Oro, 
1988).  As compared to formula milk, breast milk was reported to decrease the severity of 
NAS and need of pharmacologic treatment (Abdel-Latif et al., 2006; McQueen, Murphy-




decreasing the length of hospital stay as compared to the standard care in the hospital nursery. 
Infants with rooming-in care were reported to have shorter hospital stays and were 60% less 
likely to need opioid replacement (pharmacologic) therapy and admission to the NICU 
(Abrahams et al., 2007). Among the bed types, non-oscillating water beds were beneficial in 
consistent weight gain and decreased the need of opioid replacement therapy among NAS 
infants (Oro, 1988). Opioid replacement therapy (pharmacologic intervention) is indicated 
when the sum of three consecutive Finnegan scores is ≥ 24 (Bagley et al., 2016; Jackson, 
Ting, McKay, Galea, & Skeoch, 2004; March of Dimes, 2017). The first line of medications 
used to treat NAS infants is Ethanol-free Morphine solution of 0.4 mg/mL concentration 
(Bagley, 2016; Kraft & van den Anker, 2012). However, evidence of the efficacy of this 
approach is lacking and needs to be determined through prospective trials.  
Description of the problem 
The problem of maternal drug addiction has been prevalent since the 19th century; however, 
the teratogenic potential of maternal substance use was not discovered until the first case of 
congenital morphinism was reported in 1875 (Kocherlakota, 2014). Following this, several 
cases of neonatal withdrawal secondary to maternal opioid use, including Buprenorphine and 
Oxycontin, were reported between 1997-2002 (Kocherlakota, 2014). From 2000-2009, the 
use of opiates among pregnant women increased from 1.19 to 5.63 per 1,000 births/year 
(Patrick et al., 2013). As a result, an epidemic of NAS with a total of 21,732 infants, was 
reported in 2012 (Patrick, Davis, Lehmann, & Cooper 2015). The incidence of NAS has 
increased approximately 6-fold (1.20 to 6.7 per 1,000 hospital births/year; 450%) from 2000-
2016 (Patrick et al., 2013; Patrick et al., 2015; Strahan et al., 2019). As a result, the health 
care resource utilization associated with NAS has also increased. Reportedly, the average 




days vs. 2 days) in 2012 (Patrick et al., 2015). The LOS may extend by one more week to a 
total of 23 days if the NAS is treated by pharmacologic methods (Patrick et al., 2015). 
Likewise, there was a remarkable difference in the associated hospital charges of $66,700 
($93,400 if treated pharmacologically) among NAS infants as opposed to $3,500 for non-
NAS infants (Patrick et al., 2015). Furthermore, the aggregate hospital charges have also 
increased significantly from $732 Million to $1.5 Billion from 2009-2013, with over 75% of 
the charges attributed to Medicaid financed births (Patrick et al., 2013; Patrick et al., 2015). 
In addition, the rate of NICU admissions quadrupled (7 to 27 per 1,000 admissions) with a 
significant increase in the median length of NICU stay from 13 to 19 days between 2004-
2013 in the U.S. (Tolia et al., 2016). NICU utilization by NAS infants has increased from 
0.6% to 4% during the same period, which subsequently increased the health care burden 
nationwide (Tolia et al., 2016).  
According to a study of 28 states, state-wide trends in NAS incidence were consistent with 
the previously reported national statistics in 1999-2013 (Ko et al., 2016; Patrick et al., 2013; 
Patrick et al., 2015). There was a 300% (1.5-6.0 cases per 1,000 hospital births/year) increase 
in overall state-wide (28 states) NAS incidence as compared to 383% (1.2-5.4 cases per 1,000 
hospital births/year) nationally between 1999-2013 (Ko et al., 2016; Patrick et al., 2013; 
Patrick et al., 2015). At the state level, significant variations in NAS incidence were observed 
with an incidence as low as 0.7 cases per 1,000 births in Hawaii compared to an incidence of 
33.4 cases per 1,000 hospital births in West Virginia (Ko et al., 2016).  
These state-wide variations may be attributed to opioid prescribing rates and prevalence of 
opioid use disorder among pregnant women (Haight, Ko, Tong, Bohm, & Callaghan, 2018). 
For instance, West Virginia ranks third in opioid pain relievers (OPR) prescribing rates and 




Hockenberry, 2014). In addition, the higher incidence of NAS in West Virginia can also be 
partly explained by the elevated rates of opioid use disorder (OUD) among reproductive-aged 
and pregnant women, which reached 30 cases per 1,000 delivery hospitalizations/year in 
2014 (Haight et al., 2018; Ko et al., 2016). Similar increasing linear trends of OUD were 
reported in all other states, for instance, in Nevada the prevalence of OUD increased from 0.6 
to 4.5 from 2002-2014 (Haight et al., 2018). Nevada ranks 15th in prescribing OPRs and had a 
consistently higher OPR prescribing rate than the national figures (94.1 prescriptions/100 
persons in Nevada vs. 82.5 OPR prescriptions/100 persons nationally) in 2012 (Paulozzi et 
al., 2014). Correspondingly, the incidence of NAS in Nevada has increased from 1.1 cases 
per 1,000 births in 2003 to 4.8 cases per 1,000 births in 2013 (Ko et al., 2016). Previous 
estimates of NAS were based on the International Classification of Diseases, Ninth Revision, 
Clinical Modification (ICD-9-CM) algorithm (Agency for Healthcare Research and Quality 
[AHRQ], 2018). The ICD-9-CM coding was lacking the details necessary to differentiate 
between the two categories of NAS; therefore, previous health and financial national and 
state-wide estimates of NAS were provided after excluding the cases of presumed iatrogenic 
or therapeutic exposures (diagnostic codes 765.00-765.05, 770.7, 772.10-772.14, 777.50-
777.53, 777.6 and 779.7) (Patrick et al., 2012; Patrick et al., 2015). Effective October 1, 
2015, ICD-10-CM presents a better opportunity to delineate the two categories of NAS to 
yield more precise estimates differentiated by presumed exposure. 
While some data on NAS incidence in Nevada are available, there is a paucity of Nevada data 
related to financial estimates of NAS. With the increasing rates of opioid prescriptions and 
sequalae, such as NAS, in Nevada, it is essential to analyze the current incidence rates, health 




Purpose of the study  
The objectives of this study were to ascertain the statewide burden of NAS in Nevada from 
2016 to 2018, including incidence rates, health care utilization patterns, associated health care 
cost, and differences across demographic, clinical, and hospital-based characteristics between 
newborns with and without a NAS diagnosis among all-payer (public, private, and self-
insured) pediatric patient discharges.  
Significance of the study 
This study will contribute to the literature on NAS by providing the most recent incidence 
estimates, which are important to the formulation of public health plans and allocation of 
health resources to improve the neonatal health outcomes in Nevada. In addition, the study 
will report on the quantity of resources utilized in terms of proportion of hospital procedures, 
days and admissions to the NICU, hospital LOS and associated cost estimates to assess the 
financial impact of NAS in Nevada. Although national cost estimates are available, to our 
knowledge, this is the first study to analyze the financial impact of NAS in Nevada. 
Moreover, the implementation of the ICD-10-CM coding algorithm will allow more precise 
estimates after making a sharp distinction between NAS secondary to maternal substance use 
(diagnostic code P96.1) and NAS due to therapeutic exposure of pain-killers and sedatives 
among critically-ill neonates (diagnostic code P96.2) (AHRQ, 2018). It is expected that the 
results of this study will aid in the identification of clinical, demographic, and hospital-based 





Chapter 2. Literature review  
 
NAS as a health and fiscal challenge 
NAS poses a major global health and fiscal challenge, with increasing prevalence and rising 
health care expenditures reported in countries such as England, Canada, and Australia 
(Davies et al., 2015). In 2011, the highest prevalence rates of NAS were reported in Ontario, 
Canada with 4.29/1,000 hospital births, followed by the U.S. rate of 3.6/1,000 hospital births 
(Davies et al., 2015; Turner et al., 2015). In the U.S., NAS is a growing epidemic, with a total 
of 25,213 NAS births in 48 states in 2016 (AHRQ, 2018). Geographic variations of NAS 
incidence have been reported with the East South Central division (Kentucky, Tennessee, 
Mississippi, Alabama) having an incidence of 16.2 per 1,000 hospital births, as compared to 
the West South Central division (Oklahoma, Texas, Arkansas, Louisiana) with an incidence 
rate of 2.6 (2.3-2.9) per 1,000 hospital births (Patrick et al., 2015). Health care resource 
utilization and expenditure have also significantly increased (Filteau, Coo, & Dow, 2018; 
Patrick et al., 2013). For instance, in Canada, the number of beds occupied per day associated 
with NAS increased 3.5X from 19.7 beds to 69.4 beds between 2003-2014 (Filteau et al., 
2018). In addition, the total hospital charges associated with NAS increased by 77.7% ($11.8 
to $20.3 million) during 2010-2014 in Canada. In the U.S., the actual health care cost (after 
using cost-to-charge ratio) associated with NAS was reported to reach $316 million in 2012 
(Corr & Hollenbeak, 2017). The average cost for treating a NAS infant in the U.S. was 
$16,893 compared to $5,610 in non-NAS infants (Corr & Hollenback, 2017). These cost 
estimates do not include the costs to treat long term complications of NAS, such as 
behavioral/cognitive deficits, ear infections, lack of motor skills, and visual disturbances 
(Maguire et al., 2016). Infants with a history of NAS are more likely to have educational or 




education services (Fill et al., 2018; Morgan & Wang, 2019).  In Philadelphia, the total 
annual education cost for infants with a history of NAS was estimated to be $1,012,506 in 
2015, of which approximately $506,253 was attributed to supplying special classes to the 
children (Morgan & Wang, 2019). These estimates represent NAS due to maternal use of 
opioids only; the overall cost after including therapeutic NAS is probably higher. 
NAS as a peril of maternal drug use 
NAS results in approximately 75%-95% cases following maternal use of drugs during 
pregnancy, which has also increased significantly over the past few decades (Hudak & Tan, 
2012; Patrick et al., 2013). Between 1998-2011, the prevalence of maternal opioid use in the 
U.S. increased by 127% (0.17% in 1998, 0.39% in 2011) (Maeda, Bateman, Clancy, Creanga, 
& Leffert, 2015). Opioid-containing medications are most commonly prescribed to women of 
reproductive age (15-44 years), with a higher prescription rate of 1.6 prescriptions per 
Medicaid-enrolled women compared to 0.7 prescriptions per privately insured women in 
2012 (Ailes et al., 2015). The prevalence of prescription opioid use among Medicaid-enrolled 
women of reproductive age was higher as opposed to those privately insured (39.4% vs. 
27.7%) (Ailes et al., 2015). The most widely prescribed opioid was hydrocodone, and rates of 
prescriptions among non-Hispanic white women were nearly twice compared to non-
Hispanic black women (Ailes et al., 2015). Despite racial and ethnic differences in 
prescribing trends, variations by urban-rural status also exist (Garcia et al., 2019). According 
to recent analysis of the national electronic health record database, rural areas (particularly 
nonmetropolitan counties) were reported to have higher opioid prescriptions compared to 
urban areas (metropolitan counties) between 2014-2017 (Garcia et al., 2019). These 
variations are attributed to limited availability of alternative medical treatments, less stringent 




and patients in the rural areas (Click, Basden, Bohannon, Anderson, & Tudiver, 2017; Keyes, 
Cerdá, Brady, Havens & Galea, 2014; Monnat & Rigg, 2015). In 2012, prescribers in the 
U.S. wrote 82.5 prescriptions per 100 persons for opioid pain relievers and 37.6 prescriptions 
per 100 persons for benzodiazepines (Paulozzi et al., 2014). Statewide variations of 
prescribing OPRs, benzodiazepines, and high dose OPRs were reported, with Nevada ranking 
third in the Nation in prescribing high dose OPRs at a rate of 8.2 prescriptions per 100 
persons (Paulozzi et al., 2014). Comparable prescribing rates of high dose OPRs were 
reported in Delaware (8.8 prescriptions per 100 persons, rank 1 in the Nation) and Tennessee 
(8.7 prescriptions per 100, rank 2) (Paulozzi et al., 2014). Opioid or drug-dependent mothers 
were also 4.6X more likely to die during hospitalization (adjusted odds ratio [aOR], 4.6; 95% 
CI, 1.8 to 12.1) (Maeda et al., 2015). The problem of overprescribing has surged over the past 
few decades, which underscores the need for a multifaceted approach, including national, 
state, and provider level strategies to reverse the opioid epidemic. 
Efforts to reverse the opioid epidemic and legislative updates 
Given the association between opioid overuse among pregnant women and NAS, it is critical 
to implement prevention strategies to address the opioid crisis and promote favorable 
maternal and infant health outcomes. In 2016, the Centers for Disease Control and Prevention 
(CDC) provided guidelines for prescribing opioids for chronic pain management, which 
requires clinicians to weigh the risks and benefits associated with opioid use before 
prescribing to patients (Dowell, Haegerich & Chou, 2016). It also recommends clinicians to 
manage chronic pain with nonpharmacologic and nonopioid pharmacologic methods unless 
the expected benefits with opioid therapy outweigh the harms associated with it (Dowell et 
al., 2016). If opioid pain relievers are to be prescribed, then immediate release opioids should 




improve the communication between clinicians and patients to raise awareness about the safe 
and effective use of opioid analgesics. In 2016, the U.S. Surgeon General’s “Turn the Tide 
Campaign” was introduced to encourage physicians to adopt CDC’s prescribing guidelines, 
screening patients for potential opioid misuse, referring patients to appropriate evidence 
treatment services, and viewing or treating addiction as a chronic illness rather than a moral 
failing (American Academy of Family Physicians [AAFP], 2016). 
State legislation has also been introduced to control substance use during pregnancy. For 
example, 23 states consider substance use during pregnancy as a type of child abuse, and 
Nevada is one of those states (Guttmacher Institute, 2019). Twenty-five states, including 
Nevada, require reporting of suspected prenatal drug use by health care professionals, and 19 
states have established or funded drug treatment facilities for pregnant women (Guttmacher 
Institute, 2019). CDC has also developed the Opioid Use Disorder, Maternal Outcomes, and 
Neonatal Abstinence Syndrome Initiative Learning Community (OMNI LC) in partnership 
with the Association of State and Territorial Health Officials (ASTHO) to identify gaps in 
providing perinatal care services (Kroelinger, et al., 2019). This initiative emphasizes 5 
different core areas, namely access to quality services, providers’ education and training, data 
monitoring and evaluation, financing and coverage, and ethical and legal, and social 
considerations (Kroelinger, et al., 2019). 
One of the promising tools, for which the potential has not yet been realized was the 
Prescription Drug Monitoring Programs (PDMPs).  PDMPs form a database through which a 
prescriber can track the complete prescription history of a patient to have a better 
understanding of a patient’s behavior and previous prescription records (CDC, 2019). 
Enhancing the use of PDMPs is critical for careful and controlled opioid prescribing (CDC, 




in 2016, requires the allocation of federal funds to set up substance use facilities for pregnant 
women and establishing state PDMPs (American Society of Addiction Medicine, n.d.). 
Currently, 49 states have operational PDMPs; however, their utilization is low (Haffajee, 
Jena, & Weiner, 2015). Recently, the bill called “Prescription Drug Monitoring Act of 2019” 
was introduced in the U.S. Senate. This bill requires prescribers from each PDMP operational 
funded state to use PDMPs for searching a patient’s drug history prior to prescribing 
Schedule II-IV controlled substances (Bureau of Justice Assistance, U.S. Department of 
Justice, n.d.; National Alliance for Model State Drug Laws [NAMSDL], 2018). 
Another important CDC consideration was to implement mandatory clinical reporting and to 
set up state-wide surveillance systems for NAS (Warren et al., 2015). Previous estimates 
were based on hospital administrative data, which may be associated with a substantial delay 
before the data were available for analysis (Creanga et al., 2013; Patrick et al., 2012). With 
the surging trends of NAS, it is critical to have cases clinically reported so that immediate 
preventive strategies and policies can be formulated (Jilani et al., 2019). Although NAS was 
added to all states’ reportable disease list in 2013, currently only six states (Arizona, Florida, 
Georgia, Kentucky, Virginia, and Tennessee) have mandates for its clinical reporting (Jilani 
et al., 2019). CDC views the clinical reporting approach as a promising avenue to analyze 





Chapter 3. Methods 
Research questions 
To determine the impact of Neonatal Abstinence Syndrome among all payer inpatient 
pediatric discharges, we aimed to answer two descriptive/explorative research questions:  
Question 1: What was the incidence rate of Neonatal Abstinence Syndrome in Nevada during 
2016-2018, and how did it change over this time? 
1a. What were the incidence rates of NAS across the two most populous counties 
(Washoe vs. Clark) of Nevada? 
Question 2: What were the risk factors associated with Neonatal Abstinence Syndrome? 
2a. What were the neonatal risk factors associated with NAS? 
2b. What were the hospital-based risk factors associated with NAS? 
In addition, we aimed to address the following research questions and hypotheses. 
Question 3: What were the health care utilization patterns associated with NAS in Nevada?  
3a.  Were there any significant differences in hospital utilization patterns among NAS 
and non-NAS infants? 
• H01: There will be no difference in the length of hospital stay of NAS and non-NAS 
infants in Nevada. 
• Ha1: The length of hospital stay will be longer among NAS infants compared to non-
NAS infants in Nevada. 
• H02: There will be no difference in the proportion of hospital procedures performed 




• Ha2: The proportion of hospital procedures will be greater among NAS infants 
compared to non-NAS infants in Nevada. 
• H03: There will be no difference in the proportions of NICU admissions among NAS 
and non-NAS infants in Nevada. 
• Ha3: The proportions of NICU admissions will be greater among NAS infants 
compared to non-NAS infants in Nevada. 
• H04: There will be no difference in the days spent in the NICU among NAS and non-
NAS infants in Nevada. 
• Ha4: The NICU days will be greater among NAS infants compared to non-NAS 
infants in Nevada. 
Question 4: What were the health care expenditures associated with NAS in Nevada? 
           4a. Were there any significant differences in the health care costs between NAS and 
non-NAS infants? 
• H0: There will be no difference in the health care costs of NAS and non NAS infants 
in Nevada. 
• Ha: The health care costs of NAS infants will be higher compared to non-NAS infants 
in Nevada. 
Specific aims 
• To provide current incidence rates of NAS (2016-2018) to identify the magnitude of 
NAS in Nevada. The variations in the NAS incidence across two major population 
centers of Nevada, including Clark and Washoe counties will be crucial for regional 




• To identify health care utilization patterns in the form of length of hospitalization, 
NICU use, and the proportion of hospital procedures performed among NAS infants 
in Nevada. These data will assist in understanding the current status of state-wide 
health care delivery.  
• To perform an economic evaluation (i.e., hospital charges) of NAS in Nevada. This 
information will be vital for prioritizing the state’s financial needs or challenges. It 
will also help target prevention efforts on the high-cost aspect of NAS and to devise 
cost-effective programs to curb the costs.  
• To assess resource utilization and associated hospital charges depending on the 
payment source (public/private) to determine the burden on federally funded 
programs, including Medicaid.   
• To identify risk factors to help target prevention efforts to high-risk groups. 
• To compare demographic and clinical characteristics of NAS and non-NAS infants. 
Study design and setting 
Using multiple cross-sectional analyses and de-identified hospital administrative data, this 
geographically defined, state-wide, nested (within hospitals’ cluster) study aimed to collect 
health statistics related to NAS from 2016 through 2018 in Nevada. Nevada ranks 33rd among 
the most populous states in the United States, with a population over 3 million, of which 
657,620 eligible Nevadans’ health insurance was financed by Medicaid in 2018 (Comlossy, 
2018; U.S. Census Bureau, 2019). In 2016, the total Medicaid spending in Nevada was $3.36 
billion (Centers for Medicare & Medicaid Services, 2017; Kaiser Family Foundation, 2017). 
Most of the Nevada population is concentrated in Clark and Washoe counties (U.S. Census 
Bureau, 2019). According to recent estimates, Las Vegas and Reno are the most populous 




Neonatal Abstinence Syndrome Standardized Case Definition 
 
According to the Council of State and Territorial Epidemiologists (CSTE, n.d.) (tier 2 case 
definition for identifying NAS cases in hospital administrative data), the criteria of 
classifying confirmed and suspect NAS cases is as follows:  
• The confirmed case is a neonate with a billing diagnosis of the ICD-10 code of P96.1 
(Appendix B) appearing in any of the diagnostic fields in the hospital administrative 
data before 28 days of age. 
• The suspect case is a neonate without a billing diagnosis of ICD-10 code of P96.1 
AND contains any diagnosis code of P0414, P0417, and P041A, indicating  
maternal use of opiates, sedative-hypnotics or anxiolytics within the birth 
hospitalization or a hospitalization (Appendix B) before 28 days of age.  
Data source 
This study used secondary data from a de-identified state administrative database (i.e., Center 
for Health Information Analysis for Nevada [CHIA]).  CHIA collects all hospital admission 
discharge data for all licensed hospitals in Nevada and includes demographic information for 
patients, procedures (25 fields), diagnostic codes (33 fields), revenue and service codes (60 
fields), length of hospital stay, discharge status, and billing information (e.g., payer and 
hospital charges) (CHIA, n.d). Analyses of these data were at the aggregate level and for 
disease conditions in which n>10, (e.g., percentage of patients seen each year who were 
diagnosed with Neonatal Abstinence Syndrome). Discharge records utilized in this research 
were obtained through a Limited Data Use Agreement (LDUA) granted to the UNLV School 
of Public Health and was considered an ‘excluded’ study per the UNLV Institutional Review 





The data were acquired in digital form. The information related to variables of interest was 
collected (depending on  availability) in CHIA’s data distribution dictionary (available at 
https://www.chiaunlv.com/HealthFacilityData/DataDistributionFormats.php). The data were 
available free of cost to Nevada state public entities, including UNLV researchers and 
students. 
Data storage and protection 
Data were stored securely by password and analyzed using SAS software on a personal 
computer at UNLV. Algorithms were written to extract relevant diagnoses/procedures using 
ICD9/10, Current Procedural Terminology (CPT) and Healthcare Common Procedure Coding 
System (HCPCS) codes. Data were summarized in tables and graphs, and aggregated 
population-based estimates were calculated if sample sizes were adequate.  In compliance 
with privacy guidelines, no patient-level data were released, and any report produced that 
contained patient demographics and geographic location was aggregated. 
Data Set 
 
 The population includes all newborn hospital (inpatient) discharge records of Nevada for the 
years 2016-2018. Infants showing the ICD-10-CM code P96.1 appearing in any of 25 
diagnostic fields were identified with NAS. The suspected cases of NAS without ICD-10-CM 
code P96.1 and with codes, including P0414, P0417, and P041A were also searched (per 
CSTE definition). As a reference (i.e., non-NAS/healthy) group, uncomplicated births were 




Inclusion and Exclusion Criteria  
Infants with drug withdrawal (ICD-10-CM P96.1) following maternal drug abuse were 
included. The following records were excluded: infants with drug withdrawal following 
therapeutic drugs used (ICD-CM- P96.2) and newborns affected by reactions and 
intoxications from maternal opiates and tranquilizers used during labor and delivery (P04.0). 
Measures 
 
Demographic characteristics: Infants with a diagnosis of NAS were identified by the ICD-
10-CM code. Newborn demographic data, including   gender, race/ethnicity, income quartile 
of patient’s zip code, and location were collected. Race was classified as white, black, 
Hispanic, American Indian/Alaska Native, and Asian or Pacific Islander (API). The median 
household income was approximated to the patient zip code using the most recent (2019) 
estimates of the American Community Survey (U.S. Census Bureau, 2018). The 
classification criteria (according to 2019 estimates) for income quartiles (Q1-Q4) was 
obtained from the Health Cost and Utilization Project (HCUP) database (AHRQ, 2008) 
(Appendix D).  
Patient location was categorized into large central metropolitan, medium metro, small metro, 
and rural (includes micropolitan and noncore) according to the 2013 new county-level 
scheme developed by the National Center for Health Statistics (NCHS) (CDC, 2019). Two 
categories (micropolitan and noncore) were combined into a single rural category to preserve 
the results when sample sizes were small (n<10). Primary payer information was categorized 
as public (Medicaid), private, and uninsured, which included self-pay and no charge.  
Newborn clinical characteristics and hospital procedures: Ten clinical characteristics (i.e., 




respiratory problems, respiratory distress syndrome, neonatal jaundice, feeding difficulties, 
seizures, and sepsis) were examined. These characteristics were a priori selected based on 
published literature (Kallen et al., 2004; Lind et al., 2015; Winkelman et al., 2018; Appendix 
B). Hospital procedures to diagnose and treat respiratory, gastrointestinal, and central nervous 
system symptoms (that commonly occur in NAS infants) were also examined for the 
frequency across the sample population. The ICD-10 medical/procedure, CPT, and HCPCS 
codes (Appendix E) were used to define clinical conditions of infants (Appendix B). The 
algorithm for identifying complex chronic conditions (CCC) was adapted from a previous 
study (Feudtner, Feinstein, Zhong, Hall, & Dai, 2014). 
Neonatal and hospital-based risk factors:  Demographic and clinical characteristics of 
newborns (described above) and hospital-level factors, such as hospital academic status 
(teaching hospital vs. non-teaching hospital), hospital location (rural vs. urban), and hospital 
bed size (≤100, 101-299, ≥300) were examined as predictors of developing NAS (outcome). 
The categorization of hospital factors was adapted from previous studies (Austin & Merlo, 
2017; Young et al., 2019). 
Health care utilization and cost: Five measures, LOS, admission to the NICU, days in the 
NICU, proportion of hospital procedures, and total hospital charges were collected.  
Outcomes 
 
Incidence rates of NAS (with 95% confidence intervals) were calculated by year as the rate of 
NAS diagnoses per 1,000 delivery hospitalizations. Overall rates (with 95% confidence 
intervals) are presented by sex, payer source, median household income, and patient location. 




confidentiality. Descriptive statistics for demographic characteristics, payer source, and 
clinical characteristics were generated for newborns with and without a diagnosis of NAS. 
The NAS dependent variable was re-coded into a binary variable indicating presence 
(NAS=1) or absence of NAS (NAS=0) for the multilevel logistic regression model to identify 
predictors between NAS affected newborns and non-NAS births.  
For health care utilization and cost, the main outcomes were mean length of hospital stay 
LOS, NICU days (derived from the LOS for those admitted to the NICU), rate of NICU 
admissions, proportion of hospital procedures, and inflation-adjusted cost. The NICU use for 
each newborn was determined using the Universal Billing (UB)-92 revenue codes 174x, 
173x, 172x, and 171x. The NICU category was created on the basis of level of service 
indicated by UB-92 revenue codes in hierarchical manner with the highest being level 4 
(most acute care, 174x) and the lowest being level 1 (newborn nursery care) (Centers for 
Medicare and Medicaid Services, 2011; Noridian Healthcare Solutions, 2018; Parlett et al., 
2019). If a discharge record indicated that the patient had multiple revenue codes for the 
NICU, then the highest level of service was included after excluding the relatively lower 
levels to have four mutually exclusive categories of level of NICU utilized being expressed as 
dummy variables with 0 as “no admission to a particular level” and 1 as “admission to a 
particular level” (Appendix F).  The calculation of NICU days assumed that babies were 
transferred to the NICU within 24 hours of birth.  
For health care cost, total hospital charges (adjusted for inflation to 2019 U.S. dollars) were 
determined using the medical care component of the Consumer Price Index (Health 
Resources and Services Administration [HRSA], 2019). Total charges reflecting the total 
facility fee reported for each discharge record (not including professional fees) was 




Statistical Analysis  
A secondary analysis of hospital administrative data was conducted. The unit of analysis was 
the newborn discharge/admission (in-patient) record. All statistical procedures utilized SAS 
software version 9.4 (SAS Institute Inc., Cary, NC).  The incidence rate was determined 
arithmetically by dividing NAS-related newborn hospitalizations by the total number of 
newborn hospitalizations (with conversion to number/1000) (Table 1). The chi-square (χ2) 
test was used for conducting comparisons of categorical variables. The follow-up 
contingency table analysis (post-hoc) was conducted to obtain p-values corresponding to 
multilevel variables. The observed p-values were Bonferroni-corrected in multiple 
comparisons to prevent type 1 errors (Beasley & Schumacker, 1995). The Bonferroni 
correction was obtained by dividing the actual p-value obtained in the analysis and 
multiplying it by the number of tests performed (Beasley & Schumacker, 1995). The 
calculated p-values were then compared to a standard alpha level (0.05) to determine 
statistical significance. P-values less than 0.05 were considered statistically significant   and 
data were reported as 95% confidence intervals.  Continuous variables are presented as the 
mean ± standard deviation. Categorical variables were reported as percentages. 
For continuous measures, including health care utilization measures (LOS, NICU days, and 
total charges), the groups were compared using the independent-samples t-test. A follow-up 
bootstrap analysis was conducted to validate statistical significance and to compare with the 
classical estimates obtained through chi-square tests and independent-samples t-tests 
(Thompson, 2014). The bootstrap estimates were compared with the classical estimates to 
investigate replicability and consistency.  
For investigating potential predictors of NAS, a multilevel (2-level) logistic regression 




(i.e., hospitals). This was done to have a better understanding of the underlying heterogeneity 
of the data across hospital clusters. Multilevel modelling was conducted using the 
GLIMMIX procedure in SAS (Appendix G). In the multilevel model building process, three 
models were built to find the best fit (Table 2). The first was the null or unconditional model, 
which did not contain any patient or hospital characteristics. This incorporated only hospital 
specific random effects to model between hospital variation in terms of NAS status. The 
intraclass correlation coefficient (ICC) was manually calculated from random intercept 
variance and the standard logistic distribution (random intercept variance/random intercept 
variance + 3.29 [standard logistic distribution]) to quantify the hospital-clustering effect 
(Austin & Merlo, 2017). In other words, ICC was used to estimate the amount of variation in 
the NAS status (outcome variable) between hospitals (clusters). ICC ranges from 0 to 1 and 
this indicates the amount of variance in NAS attributable to patients (level-1) and hospitals 
(level-2) (Austin & Merlo, 2017; Pozo-Rodriguez et al., 2015).  The second model included 
all patient-related (level 1) variables as fixed effects with hospital-specific random intercept 
only to examine the relationship between these variables and incidence of NAS. A 
correlation matrix for all independent (level 1) variables included in the second model was 
calculated and examined for detecting multicollinearity (sharing variability) (Midi, Sarkar, & 
Rana, 2010) (Appendix H). Upon detection of collinearity between two variables, only one 
variable was included in the model. The third model included both patient characteristics and 
hospital characteristics in addition to hospital-specific random effects (Table 2). Risk 
estimates were shown as odds ratios, which were obtained by exponentiating the estimated 





Table 1: Variables and statistical models for each research question 
a. Gender, race, low birth weight, neonatal jaundice, transient tachypnoea, seizures, respiratory distress 
problems, respiratory difficulties, feeding difficulties, sepsis, and meconium aspiration syndrome 
(MAS).  
b. Hospital academic status (teaching hospital vs. non-teaching hospital), Hospital location (rural vs. 
urban) & hospital bed size (≤100, 101-299, ≥300). 
Question Study measures  Statistical Analysis 












• Count variable: 
Numerator (number 
of events or number 
of cases) 
• Population variable:  
Denominator (sum of 
the populations for all 
the years, 2016-
2018). 
• Crude incidence rate 
= Number of new 
NAS cases per 1,000 
hospital births 
 
• Incidence by gender, 










• NAS as a binary 
variable (NAS = 1 
[present], NAS = 0 
[absent]) 
• Level-1 variables 
(Patient related) a 
• Level 2 (or hospital 
level) b predictors 
• Provider ID was used 
as a level -2 
identification 
variable. 




• Risk estimate: Odds 
ratio 
• Significance level: P 
value < 0.05  
Health care 
utilization 
• Length of stay 
(LOS) 
• NICU admissions 
• NICU days 




• All NAS infants 
• Healthy newborns 
• Dependent variable: 
LOS 
 
• Chi-square test 
(classical 
+bootstrap) 
• Frequency of 
hospital procedures 
and NICU use 
• Independent-samples 
t-test (classical + 
bootstrap) 
• Significance level: 
P- value < 0.05  
• Bonferroni adjusted 




• Inflation adjusted 
total charges 




• All NAS infants 
• Healthy newborn 
• Dependent variable: 
Total charges 
• Independent-samples 
t-test (classical + 
bootstrap) 
• Significance level: P 






 Table 2: Multilevel model building process 
Model Model 1 Model 2 Model 3 
Model building process 
Method  No predictors, just 
random effect for the 
intercept 
Model 1 + level-1 fixed 
effectsa 
Model 2 + level-2 
predictorsb 
    
 
a. Level-1 (patient) factors: Gender, race, low birth weight, neonatal jaundice, transient 
tachypnoea, seizures, respiratory distress problems, respiratory difficulties, feeding 
difficulties, sepsis, and meconium aspiration syndrome (MAS).  
b. Level-2 (hospital) factors: Hospital academic status (teaching hospital vs. non‐teaching 




Chapter 4. Results 
 
The study population consisted of 100,845 newborns discharged from 18 Nevada hospitals 
during the years 2016-2018. The number of pediatric patients treated per hospital ranged 
from 224 to 15,542, with a median of 3,762 (25th-75th percentile: 1,466-9,121). The binary 





During the study period (2016-2018), the overall incidence of NAS was nearly 8 per 1,000 
hospital births (95% CI 7,9) in Nevada, which is 1.7X the rate previously reported in 2013 
(Figure 1, Table 3). Prior to 2016, the incidence rates of NAS in Nevada were slightly lower 
than the national rates (Figure 1). However, in 2016, the incidence of NAS in Nevada was 
nearly 23% greater compared to the national incidence reported (8.6 per 1,000 hospital births 
vs. 7 per 1,000 hospital births; Figure 1).  This trend reversal was observed for the year 2016, 
in which the more specific ICD-10 codes for identifying NAS cases (secondary to maternal 
drug abuse and neonatal iatrogenic withdrawal) became available. Additional national data 
for subsequent years (2017 and 2018) will be needed to verify if this change was due to the 
absolute increase in the incidence or may have resulted from improved identification of NAS 
cases. The overall NAS incidence varied across different regions, with Southern Nevada 
having the highest incidence rate of 8.2 (95% CI 8,9) per 1,000 hospital births compared to 
other regions (northern, Washoe, and rural) (Figure 2, Table 3). In 2016, 78% of NAS cases 
diagnosed in Nevada were residents of Clark County (230 NAS cases in Clark vs. 292 in 
Nevada; Table 3). From 2016 to 2018, the incidence rates declined slightly in Clark County, 
whereas Washoe County showed increasing trends (Figure 3). In 2016, the incidence of NAS 




in the following 2 years (Table 3). In the most recent study year (2018), Henderson still had 
the greatest incidence rate among Nevada cities (i.e., 9.7 per 1,000 hospital births) followed 
by Reno, North Las Vegas, and Las Vegas (Table 3).  
 
Figure 1: NAS rate per 1,000 Newborn Hospitalizations in Nevada and the Nation 
































































































































Figure 3: NAS rate per 1,000 among Newborn Hospitalizations (By County) 
 
 
Among different demographic groups, the overall (2016-2018) incidence of NAS was the 
highest among white newborns, occurring at a rate of 12 per 1,000 hospital births (95% CI 
11,13) (Figure 4, Table 4). The incidence of NAS among white infants decreased after 2016; 
however, a trend reversal was observed among API infants. The incidence of NAS increased 
from 0.9 to 3.8 per 1,000 newborn hospitalizations among API infants from 2016 to 2018. 
There were no differences in the overall incidence rates by gender. NAS rates also varied by 
income zip quartile, with infants born in areas of the lowest quartile with median household 
income of ≤ $47,699, having the highest overall incidence of NAS of 12.8 (95% CI 8,13) per 
1,000 hospital births (Figure 5). In terms of geography, the NAS incidence rate was highest 
in large central metropolitan areas, and lower but comparable among rural and small/medium 
metropolitan areas (Table 4). Rates differed by expected payer source, with Medicaid-
insured births having the highest NAS incidence of 13.2 (95% CI 11,15) per 1,000 hospital 
births, and 77.4% (616 out of 796) of NAS births financed by Nevada Medicaid in 2016-





























































Figure 4: NAS rate per 1,000 Newborn Hospitalizations (By Race) 
                           API=Asian Pacific Islander; Native AA= Native Alaskan American 
 
 

























































































































































































Table 3: NAS rates per 1,000 births by different Nevada geographical units, 2016-2018 




  (95% Confidence interval) 
 2016 2017 2018 2016 2017 2018 (2016 – 2018) 








Region name  
































County name  
























City name  








































a. The rates do not include suspect cases (n<10). The suspect case is a neonate without a billing diagnosis 
of ICD-10 code of P96.1 diagnosis AND contains any diagnosis code of P0414, P0417, and P041A, 
indicating maternal use of opiates, sedative-hypnotics or anxiolytics within the birth hospitalization or a 
hospitalization before 28 days of age  
b. Southern Nevada: Clark, Esmeralda, and Nye counties 
c. Northern Nevada: Carson City, Churchill, Douglas, Lyon, Mineral and Storey counties 
d.  Washoe region: Washoe county 
e. Rural Nevada Region: Elko, Eureka, Humboldt, Lincoln, Pershing, and White Pine counties 
f. Not reported due to low volume of NAS cases (n<10) 
g. Other counties: Carson City, Churchill, Douglas, Elko, Esmeralda, Humboldt, Lincoln, Lyon, Mineral, 






Table 4: NAS rates per 1,000 births by demographic and payer groups, 2016-2018 
Group criteria Number of NAS cases   Rate per 1,000 hospital births Overall Rate 
per 1,000 
                                                (95% Confidence interval) 
 2016 2017 2018 2016 2017 2018 (2016 – 2018) 
Gender 
















 Race         


































Urbanization level of residence  
Large central 
metrob 




























































a. Not reported due to low volume of NAS cases (n<10) 
b. Large central metro: Clark 
c. Medium Metro: Washoe & Storey 
d. Small metro: Carson City 
e. Rural: The two categories of micropolitan (Churchill, Douglas, Elko, Eureka, Humboldt, Lyon, Nye) and  
noncore (Esmeralda, Lander, Lincoln, Mineral, Pershing, White Pine) were combined into a single rural 
category to preserve the results when sample sizes were small.  





Demographic and Clinical characteristics 
 
Among 796 infants diagnosed with NAS and 100,049 other hospital births, the proportion of 
male and female infants was comparable among NAS and healthy newborns (48.9% females 
vs. 48.6%; p=0.6; p boot=0.91; Table 5). Compared to healthy newborns, NAS infants were 
significantly more likely to be white (69.1% vs. 45.9%; p<0.00001), living in the zip codes 
with the lowest median income (10.5% vs. 6.6%; p<0.0001), and were Medicaid-insured 
(77.4% vs. 46.6%; p=0.00004; Table 5).  
 
 Table 5: Demographic characteristics NAS infants vs. healthy births, 2016-2018 
Infants with Neonatal Abstinence Syndrome 
 
N = 796 
All Other Hospital Births 
 
N = 100,049 
 N % N % p-valuea 
Demographics  
Gender 
Female 387 48.9 48,933 48.6 0.6 
Male 407 51.1 50,991 51.1  
Race 
White 550 69.1 45,966 45.9 <0.00001 
Black 84 10.6 13,425 13.4 0.02 
Hispanic 70 8.8 22,491 22.5 <0.00001 
APIb 18 2.3 7,021 7.0 <0.00001 
Other 72 9.0 10,550 10.6 0.3 
Insurance 
Private 138 17.3 45,096 45.1  <0.00001 
Medicaid 616 77.4 46,604 46.6    0.00004 
Uninsured 42 5.3 8,349 8.3 0.001 
Income quartile      
≤$47,999 (Q1) 80 10.5 6,267 6.6 <0.00001 
$48,000-$60,999 (Q2) 389 51.1 47,521 50.3 0.6 
$61,000-$81,999 (Q3) 275 36.1 37,616 39.8 0.03 
≥$82,000 (Q4) 17 2.23 3,003 3.1 0.1 
a. The observed p-values were Bonferroni corrected   





Health outcomes for NAS infants were significantly worse than for all other Nevada infants. 
Infants with NAS were more likely than other hospital births to have complications, 
including neonatal jaundice (44.8% vs. 14.7%; p <0.001), prematurity (24.5% vs. 9.1%; p 
<0.001), feeding difficulty (19.0% vs. 2.4%; p <0.001), respiratory distress syndrome (17.3% 
vs. 6.0%; p <0.001), and transient tachypnoea of newborn (26.4% vs. 3.2%; p <0.001; Table 
6). The frequencies and proportions obtained from classical chi-square analysis (Tables 5 and 
6) were comparable with the bootstrap estimates obtained from 1000 random samples (with 
replacement) drawn from the population (Appendix I.1 & I.2).  
 
 Table 6: Clinical characteristics of NAS infants vs. healthy births, 2016-2018 
 
Infants with Neonatal Abstinence Syndrome 
                                  N = 796 
All Other Hospital Births 
N = 100,049 
 N % N % p-valuea 
Clinical Characteristics      
Neonatal Jaundice  357 44.8 14,695 14.7 <0.001 
Prematurity  195 24.5 9,114 9.1 <0.001 
Feeding Difficulty 151 19.0 2,408 2.4 <0.001 
RDSb 138 17.3 5,991 6.0 <0.001 
Transient Tachypnoea 126 26.4 3,219 3.2 <0.001 
Sepsis  76 9.5 2,341 2.3 <0.001 
Low birth weight 73 9.2 3,199 3.2 <0.001 
a. Indicates statistical significance if p-value<0.05.  





Health care utilization patterns 
 
 During the study period (2016-2018), mean LOS for newborns diagnosed with NAS was 
significantly longer compared to newborns without NAS (17 days, SD=14 vs. 2.6 days, 
SD=5, P<0.001, Figure 7, Table 7).  
 
Table 7: Health resource utilization for NAS infants vs. healthy births, 2016-2018 
 
Year  2016 
(Mean ± SD) 
2017 
(Mean ± SD) 
2018 
(Mean ± SD) 
2016 - 2018 
Neonatal Abstinence Syndrome   
Number of patients 292 247 257 796 
Mean Length of Stay 
(days) 
17.2 ± 14.5 
 
17.6 ± 13.0 
 
16.0 ± 14.0 17.0 ± 14.0 
NICUa days 18.5 ± 14.5 18.5 ± 12.8 17.5 ± 14.5 18.2 ± 14.0 
Uncomplicated Births  
Number of subjects                      33,759 33,060 33,230 100,049 
Mean Length of Stay 
(days) 
2.7 ± 5.5 
 
2.6 ± 5.0 
 
2.6 ± 4.8 
 
2.6 ± 5.0 
NICU days 10.8 ± 14.3 10.8 ± 13.0 10.5 ± 12.6 10.7 ± 13.4 






Figure 7: Mean length of stay for NAS infants vs. healthy births, 2016-2018 
 
 
NICU utilization and frequency of hospital procedures: Infants with NAS were more likely 
than other hospital births to utilize level 2 (13.0% vs. 1.2; p <0.001), level 3 (57.6% vs. 6.3; p 
<0.001), and level 4 intensive neonatal care (21.4% vs. 5.7; p <0.001) (Table 8). Moreover, 
NAS infants were more likely than other hospital births to undergo complicated hospital 
procedures, including ventilation support (13.3% vs. 4.0%; p <0.001), infusion of nutritional 
substances (11.9% vs. 2.5%; p <0.001), insertion of feeding device and resection of parts of 
gastrointestinal tract (3.1% vs. 0.6%; p <0.001), and phototherapy of the skin (21.7% vs. 7.3; 
p<0.0001) (Table 8). The proportions and p-values obtained from classical chi square (Table 
8) were comparable with the bootstrap estimates obtained from 1000 random samples drawn 








































Table 8: NICU use and hospital procedures (NAS infants vs. healthy births), 2016-2018 
Infants with Neonatal Abstinence Syndrome 
N = 796 
All Other Hospital Births 
N = 100,049 
 N % N % p-valuea 
NICU
b
 utilization      
Level 1 63 8.0 86,825 86.7 <0.0001 
Level 2 104 13.0 1,166 1.2 <0.0001 
Level 3c 459 57.6 6,318 6.3 <0.0001 
Level 4c 170 21.4 5,740 5.7 <0.0001 
Respiratory  
Ventilation Support 106 13.3 3,922 4.0 <0.0001 
Endotracheal intubation 
repair of diaphragm, and sternum   
47 6.0 1,991 2.0 <0.0001 
Gastrointestinal  
Insertion of feeding device, repair 
of esophagogastric junction 
25 3.1 582 0.6 <0.0001 
Drainage of stomach, pleural, and 
peritoneal cavity with drainage 
device 
13 1.6 237 0.2 <0.0001 
Infusion and Transfusion 
Infusion of nutritional substance  95 11.9 2,524 2.5 <0.0001 
Insertion of infusion device 38 4.8 1,646 1.6 <0.0001 
Other procedures      
Phototherapy of skin                            173 21.7 7,345 7.3 <0.0001 
   a.  Indicates statistical significance when p-value <0.05  
   b.  Neonatal intensive care unit 






Health care cost 
 
In the most recent study year (2018), inflation-adjusted mean hospital charges were  
significantly higher for newborns diagnosed with NAS compared to unaffected newborns 
($75,754, SD=66,450, 95% CI $65,974-$85,533 vs. $11,673, SD=40,174, 95% CI $11,195-
$12,152, P<0.001, Figure 8). Bootstrap estimates were comparable with the classical 
estimates (Appendix J.1). The bootstrap histogram of mean differences in the length of stays 
and health care costs showed normally distributed data (Appendix J.2 & J.3) which indicates 
that the bootstrap estimates were similar to the classical parametric estimates. Through all 
study years, most hospital charges were attributed to Nevada Medicaid programs, with more 
than 3/4th of the total charges paid by state Medicaid. On average, this amounts to $11.8 
million of the total health care cost of $14.8 million between 2016 and 2018 (Table 9).  
 





















































Table 9: Aggregate hospital charges related to NAS vs. healthy births 2016-2018 
 
Year  2016 2017 2018 
 
 Total Charges 
($) 
SD Total Charges 
($) 




Private  2,826,995 60,385 2,312,798 76,015 2,479,899 69,129 <0.001 
Medicaid  13,074,141 71,931 11,756,758 65,524 10,553,322 67,197 <0.001 
Self-pay 414,474 44,857 221,929 30,131 602,446 41,657 <0.001 
Total  16,315,611 69,289 14,291,486 66,985 13,635,668 66,488 -- 
All hospital births 
Private  132,085,357 45,218 124,757,061 40,215 148,095,334 41,712 <0.001 
Medicaid  182,746,961 54,408 179,097,978 50,006 162,605,450 42,783 <0.001 
Self-pay 18,665,078 37,784 19,564,466 27,617 19,483,438 18,865 <0.001 






Interpretation of fitted multilevel logistic regression model: In the first unconditional model, 
the intraclass coefficient (ICC) (calculated by the random intercept variance and the standard 
logistic distribution, Table 10) was 6.5%, which indicates the fraction of the variability in 
NAS incidence that is attributed to the hospitals in this study, leaving 93.5% of the 
variability in the NAS incidence to be accounted for by the patients (Austin & Merlo, 2017; 
Bell, Ene, Smiley, & Schoeneberger, 2013). A non-zero value of ICC (Table 10) indicates 
presence of a clustering effect.  Model 3 (with level-1 & level-2 predictors) appeared to be 
the best fit, given the progressively decreasing values of Akaike and Bayesian information 
criteria as progression occurred from model 1 through model 3 (Bell et al., 2013; Table 10).  
 
In the model that included both patient and hospital characteristics (Model 3; best fit), seven 
of the 12 patient characteristics and none of the hospital characteristics were significantly 
associated with the odds of developing NAS (Table 11, [Model 2]). The remaining five 
patient level factors (i.e., gender, low birth weight, meconium aspiration syndrome, 
respiratory problems, and respiratory distress syndrome) were not statistically significant. 
White infants were nearly 6 times more likely to have NAS compared to black infants (OR 
6.16 vs. 1.64, Table 11). The Medicaid insured infants were 2.8 times (OR 2.88; 95% CI 
1.98-4.2) more likely to have NAS compared to those uninsured (Table 11). NAS infants had 
higher odds of developing transient tachypnoea, seizures, neonatal jaundice, feeding 
difficulties, and sepsis compared to healthy hospital births (Table 11). None of the hospital 
characteristics, including bed size, location (rural/urban), status (teaching/non-teaching), and 






 Table 10: Multilevel model fit and hospital clustering statistics 
 




variance for ICCa 
Results indicate the 
relationship between 





Model fit statistics  
AICb 9179.62 4860.87 4792 
BICc 9181.29 4880.87 4813 
Hospital clustering statistics  
ICC                   0.065 (6.5%)                            
a. Intraclass coefficient was calculated manually, Formula of ICC:  random intercept 
variance /random intercept variance + 3.29 (3.29 is the standard logistic distribution); 
random intercept variance .2295 (model 1) 
b. Akaike’s information criterion used to examine model fitness. The progressive decreasing 
values (from model 1 to model 3) of BIC indicate improvement in model fitness.  
c. Bayesian information criterion used to examine model fitness. The progressive decreasing 





Table 11: Estimated odds ratio for multilevel logistic regression models 
 
Variable  Odds ratioa (95% Confidence Interval) 
 Model 2 Model 3 
Patient characteristics    
Female Reference  Reference 
Male  0.97 (0.83-1.13) 0.97 (0.83-1.15) 
Race    
Hispanic  Reference  Reference  
White  6.69 (5.12-8.74) 6.16 (4.67-8.14) 
Black 1.73 (1.24-2.39) 1.64 (1.17-2.30) 
Asian or Pacific islander 1.32 (0.77-2.24) 1.22 (0.71- 2.11) 
Payer   
Self-pay/uninsured  Reference  Reference  
Private  0.56 (0.37-0.83) 0.54 (0.36-0.81) 
Nevada Medicaid  2.87 (1.97-4.17) 2.88 (1.98-4.20) 
Comorbidities   
Feeding difficulty  4.60 (3.70-5.71) 4.54 (3.64-5.65) 
Neonatal Jaundice  3.30 (2.75-3.96) 3.32 (2.76-3.99) 
Seizures   2.9 (1.25-6.73) 2.96 (1.27-6.86) 
Transient Tachypnoea  2.5 (1.95-3.10) 2.43 (1.92-3.07) 
RDSb 1.12 (0.87-1.43) 1.11 (0.86-1.42) 
Sepsis  1.65 (1.20-2.25) 1.67 (1.22-2.28) 
Meconium Aspiration 
Syndrome  
1.00 (0.28-2.40) 0.98 (0.28-2.40) 
Respiratory problems  0.53 (0.22-1.27) 0.53 (0.23-1.28) 
Low birth weight 0.97 (0.70-1.35) 0.97 (0.70- 1.36) 
 
Hospital factors   
Bed size    
≥300  Reference  
101-299  0.92 (0.49-1.72) 
≤100  0.98 (0.99-2.05) 
Location    
Rural   Reference  
Urban   1.37 (0.47-2.90) 
 Status   
Non-teaching   Reference  
Teaching   0.93 (0.43-1.15) 
Type    
Non-private   Reference  
Private   0.56 (0.60-1.14) 
a. Odds ratios are conditional or cluster-specific measures of association or intra-cluster 
measures of association (Austin & Merlo, 2017).  





Results interpretation and hypotheses testing 
 
This study aimed to answer two explorative research questions (research questions 1 and 2). 
 
Question 1: What was the incidence rate of Neonatal Abstinence Syndrome in Nevada during 
2016-2018, and how did it change over this time? 
1a. What were the incidence rates of NAS across the two most populous counties (Washoe 
vs. Clark) of Nevada? 
• The overall incidence of NAS (2016-2018) in Clark County was nearly 24% higher 
than that of Washoe County. From 2016 to 2018, the incidence rates slightly declined 
in Clark County, whereas Washoe County showed increasing trends. 
Question 2: What were the risk factors associated with Neonatal Abstinence Syndrome? 
2a. What were the neonatal risk factors associated with NAS? 
• The risk of NAS was higher among white and Medicaid insured infants. The baby’s 
gender was not associated with NAS. NAS infants were more likely to be pre-term, 
low birth weight, and experience respiratory problems.  
2b. What were the hospital-based risk factors associated with NAS? 
• Hospital characteristics (e.g., location, status, type, and bed size) were not associated 





Additionally, this study answered two more questions with multiple testable hypotheses 
related to health care utilization patterns and health care cost among NAS and non-NAS 
infants.  
Health care utilization patterns: For health care utilization patterns (research question # 3), 
four hypotheses were tested and the decision to accept or reject each null hypothesis was 
made based on the significance levels and the p-values obtained. 
Question 3: What were the health care utilization patterns associated with NAS in Nevada?  
3a.  Were there any significant differences in hospital utilization among NAS and non-NAS 
infants? 
H0 3a.1: There will be no significant difference in the length of hospital stay of NAS and 
non-NAS infants in Nevada. 
• An independent-samples t-test was performed to determine if there was a difference in 
the length of hospital stay between NAS and non-NAS infants. The length of hospital 
stay was longer among NAS infants (M=17.0, SD=14.0) than non-NAS infants 
(M=2.6, SD=5.0), with a statistically significant mean difference, M = 14.4, 95% CI 
[15.6,13.2], p<0.0001. The mean difference of length of stay was statistically 
significant from zero and the observed p-value was below the significance level of 
0.05. Therefore, null hypothesis 3a.1 was rejected.   
H0 3a.2: There will be no significant difference in the proportion of hospital procedures 
performed among NAS and non-NAS infants in Nevada. 
• A chi-square test was performed to determine if the proportions of intense hospital 
procedures among NAS and non-NAS infants were significantly different. The 




the proportion of intense hospital procedures among NAS infants was statistically 
different from the proportions found in non-NAS infants. Therefore, null hypothesis 
#3a.2 was rejected.   
H0 3a.3: There will be no significant difference in the proportions of NICU admissions 
among NAS and non-NAS infants in Nevada. 
• A chi-square test was performed to determine if the proportions of NICU admissions 
among NAS and non-NAS infants were significantly different. The observed p-value 
(<0.0001) was below the significance p-value (0.05), indicating that the proportion of 
NAS infants admitted to the NICU was statistically different from the proportions 
found in non-NAS infants. Therefore, null hypothesis 3a.3 was rejected.   
H0 3a.4: There will be no significant difference in the days spent in the NICU among NAS 
and non-NAS infants in Nevada. 
• An independent-samples t-test was performed to determine if there was a difference in 
the length of NICU stay between NAS and non-NAS infants. The NICU stay was 
longer among NAS infants (M=18.2, SD =14.0) than non-NAS infants (M=10.7, 
SD=13.4), with a statistically significant difference, M = 7.5, 95% CI [9.2,4.6], 
p<0.0001). The mean difference of NICU stay was statistically significant from zero 
and the observed p-value was below the significance level of 0.05. Therefore, null 
hypothesis 3a.4 was rejected.  
Health care cost: For health care cost (research question # 4), one hypothesis was tested and 
the decision to accept or reject the null hypothesis was made based on the significance level 





Question 4: What were the health care expenditures associated with NAS in Nevada? 
4a. Were there any significant differences in the health care costs between NAS and non-
NAS infants? 
H0 4a.1: There will be no difference in the health care costs of NAS and non NAS infants in 
Nevada. 
• An independent-samples t-test was performed to determine if there were differences 
in the health care costs of treating NAS and non-NAS infants. The health care cost 
was higher among NAS infants (M=$75,753 SD =$66,488) than among non-NAS 
infants (M=$11,673, SD=$40,174), with a statistically significant difference, M = 
$64,080, 95% CI [$70,821,$63,421], p <0.0001). The mean difference of health care 
costs was statistically significant from zero and the observed p-value was below the 






Chapter 5. Discussion 
 
 
In this study of infants discharged from Nevada hospitals between 2016 and 2018, we 
observed a higher healthcare burden of NAS indicated by an increase in incidence, length of 
stay, proportion of complicated hospital procedures, NICU admissions, and associated 
hospital cost compared to uncomplicated births.  The incidence rate of NAS in 2016 was 8.6 
per 1,000 hospital births, which is nearly 28% greater compared to national rates (6.7 per 
1,000 hospital births) (Strahan et al., 2019). This difference in the incidence can be supported 
by variations in opioid prescribing rates, because Nevada had a higher opioid prescribing rate 
of 80.7 prescriptions per 100 persons compared to 66.5 prescriptions per 100 persons in the 
U.S. in 2016 (CDC, 2019c). Our study reports a slight decrease in NAS incidence in 2017-
2018. This decrease could represent a true plateau in the number of cases, or it might be due 
to decreased opioid prescribing rates, which dropped to 73 prescriptions per 100 persons in 
Nevada in 2017 (CDC, 2019c). Reportedly, Clark County had higher opioid prescribing rates 
compared to Nevada in 2016 (78 vs. 73 prescriptions per 100 persons). These rates may have 
contributed to the rising NAS incidence rates in Clark County during the same period as 
revealed by our study (CDC, 2019c) (Kim et al., 2019). 
During the study period, a higher NAS incidence was observed among Nevada Medicaid 
beneficiaries, which is consistent with previous reports (Creanga et al., 2013; Ko et al., 2016; 
Patrick et al., 2012; Wang et al., 2017). In 2016-2018, nearly 7% of the total charges ($35.4 
million of $524 million) related to all childbirths in Nevada were billed to Medicaid due to 
NAS births alone. Substantial variations in NAS incidence by race exist, with the greatest 
incidence rates among white infants (12 per 1,000 births) compared to black infants (5.4 per 
1,000 births). These racial differences in NAS incidence might be due to higher prescription 




to enroll and complete drug-replacement treatments (Ailes et al., 2015; Mitchell, Severtson, 
& Latimer, 2008; Saloner & Cook, 2013; Wang et al., 2017). The agents used to treat opioid 
dependence (i.e., Methadone and Buprenorphine) may also lead to NAS secondary to 
prenatal exposure, given their pharmacodynamic profile similar to opioids (Jones, 
Kaltenbach, & Fischer, 2010; Stockman, 2012; Whelan & Remski, 2012). The disparity in 
the treatment completion rates across racial groups was reported to be due to greater 
unemployment, financial instability, and poor access to quality health care among the black 
population (Saloner & Cook, 2013).  According to a recent Nevada based study, the rate of 
emergency room visits secondary to opioid, heroin, and cannabis increased among the white 
population compared to other racial groups in 2016, which provides an alternative 
explanation for racial disparity in terms of NAS incidence (Kim et al., 2019).   
 
This study found higher incidence rates of NAS in urban counties as compared to rural 
counties. These findings were not consistent with other nation-wide studies (Patrick et al., 
2019; Villapiano, Winkelman, Kozhimannil, Davis, & Patrick, 2017). Empirical evidence to 
explain this discordant finding is lacking; however, we believe that the rural estimates in this 
study are likely underestimated because residents from border rural counties may visit out-
of-state hospitals for delivery and may not have been admitted to Nevada hospitals. Also, the 
association of urbanization and maternal substance abuse is driven by multiple complex 
interrelationships based on macrolevel (availability of drugs and economic instability), 
microlevel (genetic vulnerability and personality traits) and local (family) dynamics which 
cannot be uncovered by a single analysis (Galea & Vlahov, 2005).  
 
Concurrent with incidence, we observed similar trends in health care utilization patterns and 




compared to other uncomplicated hospital births. In 2016-2018, the average inpatient charge 
and average LOS was seven times higher for NAS infants than for all Nevada infants.   Our 
findings of health care utilization and LOS are comparable to results from other states, 
including Tennessee, Ohio, Washington, West Virginia, Florida, and Wisconsin (Atwell, 
Welss, Gibson, Miller, & Corden, 2016; Bauer & Li, 2013; Creanga et al., 2012; Lind et al., 
2015; Ohio Department of Mental Health and Addiction services & Ohio Department of 
Health, 2013; Patrick et al., 2012; Stabler et al., 2016; Wang et al., 2017). However, direct 
comparisons of our findings with estimates of prior studies should be interpreted with caution 
because of the transition of the ICD-9 to ICD-10 coding system after 2015. Unlike the ICD-9 
code, the ICD-10 code (used in this study) allows for a clearer distinction between NAS 
secondary to maternal substance use and one that follows therapeutic exposure to drugs 
(among critically ill infants).  Estimates provided by this study are expected to have a 
relatively higher level of precision. 
We expect our LOS and hospital charges to be slightly skewed by infants who were 
presumed to be pharmacologically treated with average length of stay of more than 6 days. 
Previous studies identified NAS newborns with length of stay greater than 6 days as 
pharmacologically treated (Hudak & Tan, 2012; Patrick et al., 2015). In our study sample, 
out of 796 NAS infants, 628 infants (78%) were presumed to receive pharmacotherapy (with 
LOS > 6 days). Moreover, the extended LOS may depend on the severity of NAS symptoms, 
clinical characteristics, and type (exposure) of opioid agonist used in pharmacotherapy 
(Kakko, Heilig, & Sarman, 2008; Nezvalová-Henriksen, Spigset, & Nordeng, 2011). 
Previous studies reported significant variations in the LOS of NAS infants subsequent to 
Methadone and Buprenorphine drug replacement therapies used among their mothers 
(Kokko et al., 2008). Methadone and Buprenorphine remain the standard approach to treat 




receptors and block them (Dixon, 2019; Kleber, 2007). Methadone is a full opioid agonist, 
whereas Buprenorphine blocks opioid receptors partially, which is sufficient to reduce 
craving and intensity of withdrawal symptoms (Dixon, 2019; Kleber, 2007; Whelan & 
Remski, 2012). However, the risk of Buprenorphine being misused or diverted to the illegal 
market also exists, which underscores the importance of understanding its pharmacokinetic, 
pharmacodynamic, and safety profiles prior to use (Whelan & Remski, 2012; Yokell, Zaller, 
& Rich, 2011). Compared to Methadone, Buprenorphine is well-tolerated, more efficacious, 
and has better outcomes, when used as an opioid substitute among drug-dependent mothers 
(Whelan & Remski, 2012). Babies born after Methadone exposure remained for an 
additional 7-10 days in the hospital compared to those exposed to Buprenorphine (Jones et 
al., 2010; Kakko et al., 2008). Consistent with previous reports, our study found that over 
75% of the total hospital costs to treat NAS was attributed to Medicaid, substantiating that 
NAS placed a significant strain on the health care system (Corr et al., 2017; Patrick et al., 
2015; Winkelman et al., 2018).  
 
Limitations 
Our study has limitations that merit discussion. First, the results of the study are not 
generalizable to the entire U.S. Second, the findings are not generalizable to deliveries 
occurring outside of hospitals. We suspect our county rates to be slightly underestimated 
because individuals living in the border counties may seek medical care from neighboring 
states.  Third, a misclassification bias due to coding errors may be introduced because of the 
use of hospital administrative data for reporting conditions or diseases in the form of billing 
codes. Moreover, it may be subject to underreporting because administrative data typically 
report fewer cases than clinical reporting (Burns & Mattick, 2007). Further, the 




treatment outcomes, and type of drug exposure. Fourth, for the NICU days estimation, we 
relied on an assumption that infants get admitted to NICU within 24 hours after birth, which 
might not always be true.  Fifth, only hospital charges (not the actual costs) were calculated.  
In addition, the database used could only provide charges associated with hospital stay; the 
information related to professional fees and readmission cost was not available. Moreover, 
the cost estimates did not include expenditures to treat long-term complications due to the 
inability to track patients longitudinally in the given database. Readmission rates and 
associated expenditures were not calculated due to the lack of a “revisit variable” in the data 
source, which would link multiple hospitalizations with the same record. Next, 
discharges/admissions instead of patients were the unit of observation because identifiable 
data were not available. The use of discharges may result in duplication when multiple 
hospital admissions for the same patient occurred, and thereby overestimate hospitalization 
rates. Lastly, due to the unavailability of a “linkage key,” linking maternal records and 
neonatal records was not possible, which restricted our ability to examine maternal risk 
factors. The “probabilistic matching” approach was viewed as a potential solution to link 
these two data sets; however, after assessing the completeness of clinical and demographic 
information common to both infant and maternal records, some important clinical variables 
(e.g., delivery date, admission, discharge, and birth dates) were missing. Also, the number of 
infant records were significantly higher than the maternal records, which could have 
potentially produced several unlinked infants’ records. This discordance may be due to the 
incomplete identification of obstetric deliveries, which are typically identified by only the 







To our knowledge, this is the first study to examine health and financial burden of NAS in 
Nevada. This report provides local level data, including county and city-wise distribution of 
NAS. These findings can serve as baseline data for regional program planning and 




Given the continued rise of opioid use and prescribing rates among pregnant women, in 
Nevada, the incidence rates of NAS doubled in 2016-2018 as compared to previous rates 
reported in 2013. Subsequently, the financial burden and health resource utilization has also 
increased with a disproportionate burden on state Medicaid programs. The baseline 
information obtained from the current study provides valuable information to evaluate the 
effectiveness of different state- and system-level interventions, which have been introduced 
to combat this opioid epidemic. 
Implications for public health practice 
 
Findings from this study have several important implications for drug abuse treatment and 
prevention programs aimed at improving the health outcomes of mother-infant dyads. A 
multifaceted approach including national-, state-, and provider-level efforts will be required 
to curb the NAS epidemic. Screening and education of expectant mothers, increasing access 
to follow-up facilities, early intervention services for high-risk mothers and infants, and 
stringent regulations for preventing opioid overprescribing, including promoting the use of 
PDMPs by providers, are necessary to fight this global epidemic. More importantly, 




rapid preventive efforts without a possible time-lag associated with reporting in health 
insurance claim data. Clinical reporting will also help in detailed maternal exposure history 





This study highlights the need for additional research examining long term complications, 
readmission rates and associated health care expenditures of NAS to obtain a holistic view of 
the problem and establish a continuum of care. This study emphasizes the need for additional 
regional (Nevada) studies to explore the multidimensional spectrum in the rural-urban 
context. Prospective studies to assess rate of use/adoption (by providers) and effectiveness of 
PDMPs on opioid overprescribing rates can be a crucial step in controlling this drug 






Appendix A.  NAS Assessment Tools 





Modified Finnegan Scoring System  
 
Signs and Symptoms Score 
High pitched cry: inconsolable >15 sec or intermittently for <5 min 2 
High pitched cry: inconsolable >15 sec AND intermittently for ≥5 
min 
3 
Sleeps <1 hour after feeding 
Sleeps <2 hour after feeding 




Mild tremors: disturbed  




Markedly Hyperactive Moro 
1 
2 
Mild tremors: undisturbed  
Moderate-severe tremors: undisturbed 
1 
2 
Increased muscle tone 1-2 
Excoriation (indicate specific area): 
___________ 
1-2 
Generalized seizure  8 
Fever≥37.2 Degree Celsius  1 
Frequent yawning (≥4 in an interval) 1 
Sweating  1 
Nasal stuffiness  1 
Sneezing (≥4 in an interval) 1 
Tachypnea (rate>60/min) 2 
Poor feeding  2 
Vomiting (or regurgitation) 2 
Loose stools  2 
≤ 90% of body weight 2 
Excessive irritability  1-3 





Appendix A.2. Eat, Sleep, Console – (ESC) approach  
 
Parameter  Criteria  
Eat [E] If the infant was able to breastfeed effectively or to take ≥1 
oz from a bottle per feed 
Sleep [S] If child sleeps undisturbed for at least an hour 






Appendix B. ICD-10-CM Diagnostic codes 
Codes used for the neonatal morbidities and NAS case classification 
 
Neonatal Diagnoses  ICD-10-CM codes  
Prematurity  
 
P0730, P0738, P0739, P0731, P0732, P0733, 
P0736, P0734, P0735, P0737, P0722. P0723, 
P0724, P0725, P0726 
 
Low birth weight P0716, P0718 
Transient Tachypnea P221 
Meconium Aspiration Syndrome P 240, P241, P242, P243, P248, P249 
 
Respiratory Problems P211, P219, P230, P231, P232, P233, P234, 
P235, P236, P238, P239, P289 
Respiratory Distress Syndrome P200, P201, P209, P210, P 220, P228, P229, 
P230, P25, P260, P270, P280, P290 
Neonatal Jaundice P590, P591, P592, P593, P598, P599 
Feeding Difficulty P920, P921, P922, P923, P924, P925, P928, 
P929 
Sepsis P360, P361, P362, P363, P364, P365, P368, 
P369, P3619 
Seizures P90 
Neonatal Abstinence Syndrome 
(Confirmed cases) 
P96.1  
Neonatal Abstinence Syndrome 
(Suspect cases) * 
P0414, P0417, P041A 
















Appendix D. Classification criteria of Income Quartiles (AHRQ, 2008) 
Quartile value 
(2019) 
Income range (in $) Description  
1 1-47,999 0 to 25th percentile  
2 48,000-60,999 26th to 50th percentile 
3 61,000-81,999 51st to 75th percentile 






Appendix E. Healthcare Common Procedure Coding System  
Procedure codes  Procedure name 
6A600ZZ, 6A801ZZ, 6A650ZZ, 
6A601ZZ, 6A651ZZ, 6A800ZZ 
 
Phototherapy of skin  
5A09357, 5A09457, 5A1935Z, 5A1955Z, 
5A09557 
Respiratory ventilation  
0BH17EZ, 0BQS0ZZ, 0BH18EZ, 
0B110F4, 0BJ08ZZ, 0CJS8ZZ, 0PQ00ZZ 
 
Endotracheal intubation, repair of 
diaphragm, tracheostomy, repair of sternum   
06H033T, 06HP33Z, 02HW33Z, 
04HY33Z, 06HY33Z, 05H833Z, 
04H033Z, 02H633Z, 06H033Z, 03HP33Z, 
05H533Z, 03HY33Z, 06HY32Z, 
03HY32Z, 02WY33Z, 04HY32Z 
Insertion of infusion device  
02HW3DZ, 6A800ZZ  Insertion of intraluminal device 
3E0G76Z, 3E0336Z, 3E0436Z, 3E0536Z, Introduction of nutritional substance into 
upper GI and central vein 
0D9670Z, 0D960ZZ 
0W9G3ZZ, 0W9940Z, 0W9B40Z, 
0W9G00Z, 0W9930Z, 0W9900Z, 
0WQ80ZZ, 0WQF0ZZ, 0B9B8ZX, 
0B968ZX, 0W993ZZ, 0B9J8ZX, 
0B9F8ZX 
Drainage of stomach with drainage device,  
drainage of pleural cavity and peritoneal 
cavity, repair of chest and abdominal wall  
0DH67UZ, 0DH63UZ, 0DH60UZ, 
0DH673Z, 0DH64UZ, 0DV44ZZ, 
0DQ44ZZ 
 
Insertion of feeding device, repair of 
esophagogastric junction 
3E0F7GC, 3E0D7GC Introduction of therapeutic substance in 
respiratory tract 
BD11YZZ, BD15ZZZ, B01B1ZZ, 
B5181ZA 
 
Fluoroscopy of esophagus, heart 
BT4JZZZ, B24BZZZ, B548ZZA, 
BH48ZZZ, BT1B1ZZ, B24DYZZ 
 
Ultrasonography  
30243N1, 30233N1, 30243M1, 30233R1, 
30233L1, 30233K1 
Transfusion of non-autologous red blood 
cells into central vein, percutaneous 
approach. 
4A00X4Z, 4A133B1 Measurement of central nervous system 
activity, monitoring of arterial pressure 
0DTB0ZZ, 0DTJ0ZZ, 0D1B0Z4, 
0DBN0ZZ 
Resection of ileum, resection of appendix   
HZ2ZZZZ, HZ91ZZZ, HZ81ZZZ, 
HZ99ZZZ 






Appendix F. Dummy variable representation for NICU utilization 
Levels of care  Level 4 Level 3 Level 2 Level 1 
174 1 x x x 
173 0 1 x x 
172 0 0 1 x 
171 1 0 0 0 
Note: 
x = 0 or 1 (depends if patient directly admitted to the 
highest or critical level or transferred from lower level 
to the highest) 
1 = admission 






Appendix G. SAS codes 
SAS code for GLIMMIX Procedure 
 
 
Model 1  
proc glimmix data= work. import method=quad; 
class ProviderID; 
model NAS_Status = /dist=binomial solution cl; 
random intercept /subject=ProviderID; 
title “Null Multilevel logistic regression model”; 
run; 
 
Model 2  
 
proc glimmix data=WORK.import1 method=quad;  
class ProviderID GenderCode RaceCode Insurance LBW_R TT_R Seiz_R MAS_R 
RespProb_R RespDist_R NJ_R FD_R Sepsis_R; 
model NAS_Status = GenderCode RaceCode Insurance LBW_R premature_R TT_R 
Seiz_R MAS_R RespProb_R RespDist_R NJ_R FD_R Sepsis_R / dist=binomial 
solution cl; 
random intercept /subject=ProviderID; 
output out=out2 (keep = ID pred2) pred(ilink) = pred2; 





proc glimmix data=WORK.import1 method=quad; 
class ProviderID GenderCode RaceCode Profit_R Teaching_R Location_R BedCode 
Insurance LBW_R TT_R Seiz_R MAS_R RespProb_R RespDist_R NJ_R FD_R 
Sepsis_R; 
model NAS_Status = GenderCode RaceCode CountyResidence Income_Quartile 
Profit_R Teaching_R Location_R BedCode Insurance LBW_R premature_R TT_R 
Seiz_R MAS_R RespProb_R RespDist_R NJ_R FD_R Sepsis_R /dist=binomial 
solution cl; 
random intercept /subject=ProviderID; 
output out=out2 (keep = ID pred2) pred(ilink) = pred2; 











Appendix H. Correlations to assess potential collinearity among model predictors 
Variable 1 Variable 2 Pearson correlation  
Preterm birth  LBWa 0.674 
Preterm birth  Transient tachypnea  0.144 
Preterm birth  RDSb 0.339 
Preterm birth Neonatal jaundice  0.297 
Preterm birth Feeding difficulty 0.161 
Preterm birth Sepsis  0.172 
Preterm birth Seizures  0.009 
LBW RDS 0.244 
LBW Neonatal jaundice  0.215 
LBW Feeding difficulty  0.111 
LBW Sepsis  0.122 
LBW Transient tachypnea  0.089 
LBW  Seizures  0.007 
a. Low birth weight 










Appendix I. Bootstrapped chi-square outputs 
Appendix I.1. Bootstrapa chi-square tests output, demographic characteristics 
 
 
 NAS Infants All Other Hospital 
Births 
p-valueb 
 % %  
Demographics     
Gender    
Female 48.90 48.60 0.91 
Male 51.00 51.10  
Race    
White 69.10 45.90 <0.0001 
Black 10.60 13.40  
Hispanic 8.80 22.50  
APIc 2.30 7.00  
Other 9.00 10.60  
Insurance    
Private 17.30 45.10 <0.0001 
Medicaid 77.40 46.60  
Uninsured 5.30 8.30  
Income quartile    
≤$47,999 (Q1) 10.50 6.63 <0.0001 
$48,000-$60,999 (Q2) 51.00 50.30  
$61,000-$81,999 (Q3) 36.10 39.80  
$82,000 (Q4) 2.23 3.10  
a. Bootstrap estimates were from 100 random samples with replacement  
b. Observed p value statistically significant if <0.05 







Appendix I.2. Bootstrapa chi-square tests output, clinical characteristics 
 





Prematurity  24.5 9.1 <0.001 
Low birth weight 9.2 3.2 <0.001 
Transient Tachypnea 26.4 3.2 <0.001 
Respiratory Distress 
Syndrome  
17.3 6.0 <0.001 
Neonatal Jaundice  44.8 14.7 <0.001 
Feeding Difficulty 19.0 2.4 <0.001 
Sepsis  9.5 2.3 <0.001 
a. 1000 random samples with replacement  













 % %  
NICU utilization 
Level 1 7.91 86.70 <0.0001 
Level 2 13.00 1.17 <0.0001 
Level 3 57.60 6.31 <0.0001 
Level 4 21.40 5.70 <0.0001 
Respiratory  
Ventilation Support 13.30 3.90 <0.0001 
Endotracheal intubation 
repair of diaphragm, and sternum   
5.90 2.00 <0.0001 
Gastrointestinal  
Insertion of feeding device, repair of 
Esophagogastric junction 
3.10 0.60 <0.0001 
Infusion  
Insertion of infusion device 4.80 1.60 <0.0001 
Infusion of nutritional substance  11.90 2.50 <0.0001 









Appendix J. Bootstrapped independent-samples t- test 
Appendix J.1. Classical and Bootstrapped t- tests results comparison 
 
Tests Standard error  95% confidence intervals  
Classical T test 
Mean LOS 0.58 days -15.50, -13.20 
 Mean health care cost $2,850 -72,719, -61,523 
Bootstrap estimates  
 Length of stay 0.60 days -15.60, -13.30 







Appendix J.2. Bootstrap distribution of difference in means length of stay 
 
 
(Differences in the mean length of stay) 
  

















































Appendix K. List of Acronyms  
AAP American Academy of Pediatrics 
AA Alaskan American 
AAFP American Academy of Family Physicians 
ASTHO  Association of State and Territorial Health Officials 
AHRQ Agency for Healthcare Research and Quality 
API Asian or Pacific Islander 
CI  Confidence Interval 
CDC Centers for Disease Control and Prevention 
CHIA Center for Health Information Analysis 
CARA Comprehensive Addiction and Recovery Act 
DHHS Department of Health and Human Services 
DHCFP Division of Healthcare Financing and Policy 
ESC Eat, Sleep, Console 
HIPAA Health Insurance Portability and Accountability Act 
HRSA Health Resources and Services Administration 
ICD-9-CM International Classification of Diseases, Ninth Revision, Clinical 
Modification 
ICD-10-CM International Classification of Diseases, Tenth Revision, Clinical 
Modification 
IRB Institutional Review Board 
LBW Low birth weight 
LOS Length of stay 
NAS Neonatal Abstinence Syndrome 
NASS Neonatal Abstinence Scoring System 
NICU Neonatal Intensive Care Unit 
NWI Narcotic Withdrawal Index 
NAMSDL National Alliance for Model State Drug Laws 
OMNILC Opioid Use Disorder, Maternal Outcomes, and Neonatal Abstinence 
Syndrome Initiative Learning Community 
OPR Opioid prescribing rate 
OUD Opioids use disorder 
PDMP Prescription Drug Monitoring Program 
RDS Respiratory Distress Syndrome 
SPH School of Public Health 






Appendix L. List of Definitions  
 
Average length of stay  The average number of days in an in-patient setting 
Binary variable  Variable with two responses 
Bootstrap analysis  This allows estimation of the sampling distribution of any 
statistic using random sampling. 
Collinearity  Correlation between two independent variables 
Diagnostic code  A tool to group and identify diseases and conditions in health 
care data 
In-utero exposure Exposure to licit or illicit substances in the womb 
Kangaroo care Skin to skin contact between parent (typically mother) and baby  
Meconium aspiration 
syndrome  
The baby has passed meconium (stool) into the amniotic fluid 
during labor or delivery 
Medicaid discharge A person who has Medicaid as a payer source 
NAS hospitalization 
rate 
The number of in-patient NAS hospitalizations divided by the 
number of live births to Nevada residents, giving birth in 
Nevada. The rate is presented in units per 1,000 hospital births. 
NICU Specialized care unit for critically- ill or premature babies 
Opioids  Class of drugs that include the illegal drug heroin, synthetic 
opioids such as fentanyl and pain relievers available legally by 
prescription, such as Oxycontin, morphine, hydrocodone etc. 
Preterm birth Babies born prior to 37 completed weeks of gestation 




Breathing problem which occurs when the lungs of the baby are 
not fully developed 
Revenue code  Revenue codes are 3-digit numbers that are used to describe the 
setting in which a patient receives a specific type of treatment 
Rooming-in Practice in which a baby’s crib is kept by the side of the 
mother’s bed 








Abdel-Latif, M. E., Pinner, J., Clews, S., Cooke, F., Lui, K., Oei, J. (2006). Effects of 
Breast Milk on the Severity and Outcome of Neonatal Abstinence Syndrome 
Among Infants of Drug-Dependent Mothers. PEDIATRICS, 117(6), e1163-e1169. 
doi:10.1542/peds.2005-1561. Retrieved from 
https://pediatrics.aappublications.org/content/pediatrics/117/6/e1163.full.pdf 
 
Abrahams, R. R., Kelly, S. A., Payne, S., Thiessen, P. N., Mackintosh, J., & Janssen, P. A. 
(2007). Rooming-in compared with standard care for newborns of mothers using 
methadone or heroin. Canadian family physician Medecin de Famille 
Canadien, 53(10), 1722–1730. Retrieved from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2231437/ 
 
Agency for Healthcare Research and Quality (AHRQ). Health cost and utilization Project 
(HCUP). (2008, September 17). HCUP-NIS Description of Data Elements. 
Retrieved from https://hcup-us.ahrq.gov/db/vars/zipinc_qrtl/nisnote.jsp 
 
Agency of Healthcare Research and Quality. (2018). Trends in Neonatal Abstinence 
Syndrome Births in the United States. Retrieved from The Healthcare Cost and 




Ailes, E. C., Dawson, A. L., Lind, J. N., Gilboa, S. M., Frey, M. T., Broussard, C. S., … 
Centers for Disease Control and Prevention (CDC) (2015). Opioid prescription 




Morbidity and mortality weekly report, 64(2), 37–41. Retrieved from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4584597/ 
 
American Academy of Family Physicians. (2016, August 24). U.S. Surgeon General Turn 
the Tide Announcement. Retrieved from https://www.aafp.org/patient-care/public-
health/pain-opioids/turn_the_tide.html 
 
American Society of Addiction Medicine. (n.d.). Summary of the Comprehensive Addiction 




Atwell, K. A., Welss, H. B., Gibson, C., Miller, R., & Corden, T. E. (2016). Neonatal 
Abstinence Syndrome and Maternal Substance Use in Wisconsin, 2009-
2014. Wisconsin Medical Society, 115(6), 287-293. 
 
Austin, P. C., & Merlo, J. (2017). Intermediate and advanced topics in multilevel logistic 
regression analysis. Statistics in Medicine, 36(20), 3257-3277. 
doi:10.1002/sim.7336 
 
Bagley, S. M., Wachman, E. M., Holland, E., & Brogly, S. B. (2014). Review of the 
assessment and management of neonatal abstinence syndrome. Addiction science & 
clinical practice, 9(1), 19. doi:10.1186/1940-0640-9-19. Retrieved from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4166410/ 
 
Bauer, A. M., & Li, Y. (2013). Neonatal Abstinence Syndrome and Maternal Substance 
Abuse in Tennessee:1999-2011. Retrieved from Tennessee Department of Health, 








Beasley, T. M., & Schumacker, R. E. (1995). Multiple Regression Approach to Analyzing 
Contingency Tables: Post Hoc and Planned Comparison Procedures. The Journal of 
Experimental Education, 64(1), 79-93. doi:10.1080/00220973.1995.9943797. 
 
Bell, B. A., Ene, M., Smiley, W., & Schoeneberger, J. A. (2013). A Multilevel Model 
Primer Using SAS Proc Mixed. Paper presented at SAS Global Forum. 
 
Blasnik, M. 2007 (revised 2010). "RECLINK: Stata module to probabilistically match 
records," Statistical Software Components S456876, Boston College Department of 
Economics. Retrieved from https://ideas.repec.org/s/boc/bocode2.html 
 
Bureau of justice assistance U.S. Department of Justice. (n.d.). Prescription Drug 




Burns, L., & Mattick, R. (2007). Using population data to examine the prevalence and 
correlates of neonatal abstinence syndrome. Drug and Alcohol Review, 26(5), 487-
492. doi:10.1080/09595230701494416 
 
Centers for Disease Control and Prevention. (2019a, April 29). What States Need to Know 





Centers for Disease Control and Prevention. (2019b, December 2). Data Access - Urban 
Rural Classification Scheme for Counties. Retrieved from 
https://www.cdc.gov/nchs/data_access/urban_rural.htm 
 
Centers for Disease Control and Prevention. (2019c, July 11). Prescription Opioid Data. 
Retrieved from https://www.cdc.gov/drugoverdose/data/prescribing.html 
 
Center for Health Information Analysis for Nevada. (n.d.). About Us. Retrieved from 
https://www.chiaunlv.com/AboutUs/AboutUs.php 
 
Centers for Medicare and Medicaid services (2011). MLN matters: Information for 




Centers for Medicare & Medicaid Services (2017). Health Expenditures by State of 
Residence. Retrieved (date accessed) at http://www.cms.gov/Research-Statistics-
Data-and-Systems/StatisticsTrends-and-
Reports/NationalHealthExpendData/Downloads/resident-stateestimates.zip      
 
Charles, M. K., Cooper, W. O., Jansson, L. M., Dudley, J., Slaughter, J. C., & 
Patrick, S. W. (2017). Male Sex Associated with Increased Risk of Neonatal 
Abstinence Syndrome. Hospital Pediatrics, 7(6), 328-334. doi:10.1542/hpeds.2016-
0218 
 
Click, I. A., Basden, J. A., Bohannon, J. M., Anderson, H., & Tudiver, F. (2017). Opioid 




Misuse, 53(4), 533-540. doi:10.1080/10826084.2017.1342659. Retrieved from 
https://www.ncbi.nlm.nih.gov/pubmed/28857643 
 
Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd ed.). Retrieved 
from http://utstat.toronto.edu/~brunner/oldclass/378f16/readings/CohenPower.pdf 
 




Corr, T. E., & Hollenbeak, C. S. (2017). The economic burden of neonatal abstinence 
syndrome in the United States. Addiction, 112(9), 1590-1599. 
doi:10.1111/add.13842 
 
Council of State and Territorial Epidemiologists. (n.d.). Neonatal Abstinence Syndrome 




Crampton, R.E.M., Gruchala, N.E. 2013. Babies breaking bad: neonatal and iatrogenic 
withdrawal syndromes. Current opinion Pediatrics. 25(4). 532-542. DOI: 




Creanga, A., Sabel, J., Ko, J., Wasserman, C., Shapiro-Mendoza, C., Taylor, P., … 
Paulozzi, L.J. (2013). Maternal Drug Use and Its Effect on Neonates. Obstetric 








Creanga, A. A., Sabel, J. C., Jean, Y. K., Wasserman, C. R., Shapiro-Mendoza, C. K., 
Taylor, P., & Paulozzi, L. J. (2012). Maternal drug use and its effect on neonates: a 






D'Apolito, K. (1999). Comparison of a Rocking bed and Standard beds for Decreasing 
Withdrawal Symptoms in Drug-Exposed Infants. MCN, The American Journal of 






Davies, H., Gilbert, R., Johnson, K., Petersen, I., Nazareth, I., O'Donnell, M., … Gonzalez-
Izquierdo, A. (2015). Neonatal drug withdrawal syndrome: cross-country 
comparison using hospital administrative data in England, the USA, Western 
Australia and Ontario, Canada. Archives of Disease in Childhood - Fetal and 
Neonatal Edition, 101(1), 26-30. doi:10.1136/archdischild-2015-308948. Retrieved 
from https://fn.bmj.com/content/101/1/26.long 
 
Dixon, D. W. (2019, November 11). What is the mechanism of action of buprenorphine in 







Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC Guideline for Prescribing Opioids 
for Chronic Pain--United States, 2016. JAMA, 315(15), 1624–1645. 
doi:10.1001/jama.2016.1464. Retrieved from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390846/ 
 
Faul, F., Erdfelder, E., Buchner, A., & Lang, A.-G. (2009). Statistical power analyses using 
G*Power 3.1: Tests for correlation and regression analyses. Behavior Research 





Faul, F., Erdfelder, E., Lang, A.-G., & Buchner, A. (2007). G*Power 3: A flexible 
statistical power analysis program for the social, behavioral, and biomedical 





Feudtner, C., Feinstein, J. A., Zhong, W., Hall, M., & Dai, D. (2014). Pediatric complex 
chronic conditions classification system version 2: updated for ICD-10 and complex 
medical technology dependence and transplantation. BMC Pediatrics, 14(1). 





Filippelli, A. C., White, L. F., Spellman, L. W., Broderick, M., Highfield, E. S., Sommers, 
E., & Gardiner, P. (2012). Non-Insertive Acupuncture and Neonatal Abstinence 
Syndrome: A Case Series from an Inner-City Safety Net Hospital. Global advances 
in health and medicine, 1(4), 48–52. doi:10.7453/gahmj.2012.1.4.007. Retrieved 
from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3783013/ 
 
Fill, M. A., Miller, A. M., Wilkinson, R. H., Warren, M. D., Dunn, J. R., Schaffner, W., & 
Jones, T. F. (2018). Educational Disabilities Among Children Born with Neonatal 
Abstinence Syndrome. Pediatrics, 142(3), e20180562. doi:10.1542/peds.2018-0562. 
Retrieved from https://pediatrics.aappublications.org/content/142/3/e20180562 
 
Filteau, J., Coo, H., & Dow, K. (2018). Trends in incidence of neonatal abstinence 
syndrome in Canada and associated healthcare resource utilization. Drug and 
Alcohol Dependence, 185, 313-321. doi: 10.1016/j.drugalcdep.2017.12.019 
 
Finnegan, L. P., Hagan, T., & Kaltenbach, K. A. (1991). Scientific foundation of clinical 
practice: opiate use in pregnant women. Bulletin of the New York Academy of 
Medicine, 67(3), 223–239. Retrieved from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1807935/ 
 
Galea, S., & Vlahov, D. (2005). Urban health: Evidence, Challenges, and 
Directions. Annual Review of Public Health, 26(1), 341-365. doi: 
10.1146/annurev.publhealth.26.021304.144708 
 
Garcia, M. C., Heilig, C. M., Lee, S. H., Faul, M., Guy, G., Lademarco, M. F., … Centers 
for Disease Control and Prevention (CDC) (2019). Opioid prescribing rates in 
nonmetropolitan and metropolitan counties among primary care providers using an 




mortality weekly report, 68(2), 25–30. Retrieved from 
https://www.cdc.gov/mmwr/volumes/68/wr/mm6802a1.htm?s_cid=mm6802a1_w4 
 
Green, S.B. (2010, June 10). How many subjects does it take to do a regression analysis? 
Multivariate Behavioral Research, 26(3), 499-510. Retrieved from https://www-
tandfonline-com.ezproxy.library.unlv.edu/doi/abs/10.1207/s15327906mbr2603_7 
 
Grossman, M. R., Berkwitt, A. K., Osborn, R. R., Xu, Y., Esserman, D. A., Shapiro, E. D., 
& Bizzarro, M. J. (2017). An Initiative to Improve the Quality of Care of Infants 
with Neonatal Abstinence Syndrome. Pediatrics, 139(6), e20163360. 




Guttmacher Institute. (2019, September 1). Substance Use During Pregnancy-State laws 
and policies. Retrieved from https://www.guttmacher.org/state-
policy/explore/substance-use-during-pregnancy 
 
Haffajee, R. L., Jena, A. B., & Weiner, S. G. (2015). Mandatory use of prescription drug 
monitoring programs. JAMA, 313(9), 891–892. doi:10.1001/jama.2014.18514. 
Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4465450/ 
 
 
Haight, S. C., Ko, J. Y., Tong, V. T., Bohm, M. K., & Callaghan, W. M. (2018). Opioid Use 
Disorder Documented at Delivery Hospitalization — United States, 1999–
2014. MMWR. Morbidity and Mortality Weekly Report, 67(31), 845-849. 






Hall, R. W., & Shbarou, R. M. (2009). Drugs of choice for sedation and analgesia in the 
neonatal ICU. Clinics in perinatology, 36(1), 15–26. doi: 10.1016/j.clp.2008.09.007. 
Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2662993/ 
 
Hamdan, A. H. (2019, February 3). Neonatal Abstinence Syndrome: Practice Essentials, 
Background, Pathophysiology. Retrieved from 
https://emedicine.medscape.com/article/978763-overview 
 
Harron, K., Gilbert, R., Cromwell, D., & Van der Meulen, J. (2016). Linking Data for 
Mothers and Babies in De-Identified Electronic Health Data. PLOS ONE, 11(10), 
e0164667. doi:10.1371/journal.pone.0164667 
 
Health Resources and Services Administration. (2019, May 6). Consumer Price Index (CPI) 
for Medical Care. Retrieved from https://www.hrsa.gov/get-health-
care/affordable/hill-burton/cpi.html 
 
Hudak, M.L., Tan, R.C.2012. Neonatal drug withdrawal. Pediatrics. 129(2). e540-e560. 
Retrieved from https://pediatrics.aappublications.org/content/129/2/e540 
 
Hünseler, C., Brückle, M., Roth, B., & Kribs, A. (2013). Neonatal Opiate Withdrawal and 
Rooming-In: A Retrospective Analysis of a Single Center Experience. Klinische 
Pädiatrie, 225(05), 247-251. doi:10.1055/s-0033-1347190. Retrieved from 
https://www.ncbi.nlm.nih.gov/pubmed/23966227 
 
IBM Corp. Released 2019. IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY: 
IBM Corp. 
 
Jackson, L., Ting, A., McKay, S., Galea, P., & Skeoch, C. (2004). A randomised controlled 




of disease in childhood. Fetal and neonatal edition, 89(4), F300–F304. 
doi:10.1136/adc.2003.033555. Retrieved from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1721707/ 
 
Jilani, S. M., Frey, M. T., Pepin, D., Jewell, T., Jordan, M., Miller, A. M., … Reefhuis, J. 
(2019). Evaluation of State-Mandated Reporting of Neonatal Abstinence Syndrome 
— Six States, 2013–2017. MMWR. Morbidity and Mortality Weekly Report, 68(1), 
6-10. doi:10.15585/mmwr.mm6801a2. Retrieved from 
https://www.cdc.gov/mmwr/volumes/68/wr/pdfs/mm6801a2-H.pdf 
 
Jones, H. E., Kaltenbach, K., Heil, S. H., Stine, S. M., Coyle, M. G., Arria, A. M., & 
Fischer, G. (2010). Neonatal Abstinence Syndrome after Methadone or 
Buprenorphine Exposure. The New England Journal of Medicine, 363(24), 2320-
2330. 
 
Jones, H. E., Seashore, C., Johnson, E., Horton, E., O'Grady, K. E., Andringa, K., … 
Holmes, A. V. (2016). Psychometric assessment of the Neonatal Abstinence Scoring 
System and the MOTHER NAS Scale. The American Journal on Addictions, 25(5), 
370-373. doi:10.1111/ajad.12388. Retrieved from 
https://onlinelibrary.wiley.com/doi/full/10.1111/ajad.12388   
  
Källén, B. (2004). Neonate Characteristics After Maternal Use of Antidepressants in Late 






Kaiser Family Foundation. (2017). Medicaid spending – The Henry J. Kaiser family 
Foundation. Retrieved from https://kff.org/state-category/medicaid-chip/medicaid-
spending/ 
 
Keyes, K. M., Cerdá, M., Brady, J. E., Havens, J. R., & Galea, S. (2014). Understanding the 
rural-urban differences in nonmedical prescription opioid use and abuse in the 
United States. American journal of public health, 104(2), e52–e59. 
doi:10.2105/AJPH.2013.301709. Retrieved from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3935688/ 
 
Kim, P. C., Yoo, J. W., Cochran, C. R., Park, S., Chun, S., Lee, Y., & Shen, J. J. (2019). 
Trends and associated factors of use of opioid, heroin, and cannabis among patients 
for emergency department visits in Nevada. Medicine, 98(47), e17739. 




Kleber, H. D. (2007). Pharmacologic treatments for opioid dependence: detoxification and 
maintenance options. Dialogues in clinical neuroscience, 9(4), 455-470. Retrieved 
from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202507/ 
 
Ko, J. Y., Patrick, S. W., Tong, V. T., Patel, R., Lind, J. N., & Barfield, W. D. (2016). 
Incidence of Neonatal Abstinence Syndrome — 28 States, 1999–2013. MMWR. 
Morbidity and Mortality Weekly Report, 65(31), 799-802. 






Kocherlakota, P. (2014). Neonatal Abstinence Syndrome. Pediatrics, 134(2). e547-561. 
doi:10.1542/peds.2013-3524. Retrieved from 
https://pediatrics.aappublications.org/content/134/2/e547 
 
Kraft, W. K., & van den Anker, J. N. (2012). Pharmacologic management of the opioid 
neonatal abstinence syndrome. Pediatric clinics of North America, 59(5), 1147–
1165. doi:10.1016/j. pcl.2012.07.006. Retrieved from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709246/ 
 
Kroelinger, C.D., Rice, M.E., Cox, S., Hickner, H.R., Weber, M.K., Romero, L.…. Centers 
for Disease Control and Prevention (CDC) (2019). State Strategies to Address 
opioid Use Disorder Among Pregnant and Postpartum Women and Infants 
Prenatally exposed to Substances, Including Infants with Neonatal Abstinence 
Syndrome. MMWR Morbidity and mortality weekly report, 68:777–783. 
DOI: http://dx.doi.org/10.15585/mmwr.mm6836a1. Available at 
https://www.cdc.gov/mmwr/volumes/68/wr/mm6836a1.htm 
 
Lenth, R. V. (2001). Some Practical Guidelines for Effective Sample Size 
Determination. The American Statistician, 55(3), 187-193. 
doi:10.1198/000313001317098149. Retrieved from 
https://www.tandfonline.com/doi/abs/10.1198/000313001317098149 
 
Lind, J. N., Petersen, E. E., Lederer, P. A., Phillips-Bell, G. S., Perrine, C. G., Li, R., & 
Anjohrin, S. (2015). Infant and maternal characteristics in neonatal abstinence 
syndrome--selected hospitals in Florida, 2010-2011. Morbidity and Mortality 






Lisonkova, S., Richter, L. L., Ting, J., Muraca, G. M., Wen, Q., Mehrabadi, A., … Lyons, J. 
(2019). Neonatal Abstinence Syndrome and Associated Neonatal and Maternal 
Mortality and Morbidity. Pediatrics, 144(2), e20183664. doi:10.1542/peds.2018-
3664 Retrieved from https://pediatrics.aappublications.org/content/144/2?current-
issue=y 
 
Logan, B. A., Brown, M. S., & Hayes, M. J. (2013). Neonatal abstinence syndrome: 
treatment and pediatric outcomes. Clinical obstetrics and gynecology, 56(1), 186–
192. doi: 10.1097/GRF.0b013e31827feea4. Retrieved from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3589586/ 
 
Maeda, A., Bateman, B., Clancy, C., Creanga, A., & Leffert, L. (2015). Opioid Abuse and 
Dependence During Pregnancy. Obstetric Anesthesia Digest, 35(4), 191-192. doi: 
10.1097/01.aoa.0000472709. 26833.de 
 
Maichuk, G. T., Zahorodny, W., & Marshall, R. (1999). Use of Positioning to Reduce the 
Severity of Neonatal Narcotic Withdrawal Syndrome. Journal of 
Perinatology, 19(7), 510-513. doi:10.1038/sj.jp.7200260. Retrieved from 
https://www.nature.com/articles/7200260.pdf 
 
Maguire, D. J., Taylor, S., Armstrong, K., Shaffer-Hudkins, E., Germain, A. M., 
Brooks, S. S., … Clark, L. (2016). Long-Term Outcomes of Infants with Neonatal 
Abstinence Syndrome. Neonatal Network, 35(5), 277-286. doi:10.1891/0730-









McQueen, K., & Murphy-Oikonen, J. (2016). Neonatal Abstinence Syndrome. The New 




McQueen, K. A., Murphy-Oikonen, J., Gerlach, K., & Montelpare, W. (2011). The Impact 
of Infant Feeding Method on Neonatal Abstinence Scores of Methadone-Exposed 
Infants. Advances in Neonatal Care, 11(4), 282-290. 




Midi, H., Sarkar, S., & Rana, S. (2010). Collinearity diagnostics of binary logistic 
regression model. Journal of Interdisciplinary Mathematics, 13(3), 253-267. 
doi:10.1080/09720502.2010.10700699 
 
Mitchell, M. M., Severtson, S. G., & Latimer, W. W. (2008). Pregnancy and Race/Ethnicity 
as Predictors of Motivation for Drug Treatment. The American Journal of Drug and 
Alcohol Abuse, 34(4), 397-404. doi:10.1080/00952990802082172. Retrieved from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714164/ 
 
Monnat, S. M., & Rigg, K. K. (2015). Examining Rural/Urban Differences in Prescription 








Morgan, P.L., & Wang, Y. (2019). The Opioid Epidemic, Neonatal Abstinence Syndrome, 
and Estimated Costs for Special Education Services. American Journal of Managed 




National Alliance for Model State Drug Laws. (2018, December 15). Model Laws. 
Retrieved from https://namsdl.org/model-laws/?fwp_topic=cs 
 
Nezvalová-Henriksen, K., Spigset, O., & Nordeng, H. (2011). The effects of codeine on 
pregnancy outcome: Results from a large population-based cohort 
study. Reproductive Toxicology, 31(2), 263-263. 
doi:10.1016/j.reprotox.2010.12.040. Retrieved from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3214255/?report=reader 
 




Ohio Department of Mental Health and Addiction services, & Ohio Department of Health. 
(2013). Neonatal Abstinence Syndrome and Drug use among pregnant women in 







Oro, A. S. (1988). Waterbed Care of Narcotic-Exposed Neonates. American Journal of 
Diseases of Children, 142(2), 186. doi:10.1001/archpedi.1988.02150020088036. 
Retrieved from https://jamanetwork.com/journals/jamapediatrics/fullarticle/513902 
 
Parlett, L., Agiro, A., Brown, S., Wilt, M., Portzline, A., Verburg, J., … DeVries, A. 
(2019). Drivers of hospital length of stay in Medicaid and commercially insured 
mother-infant pairs with a diagnosis of neonatal abstinence syndrome. Medical 
Care, 57(12), 977-983. doi:10.1097/mlr.0000000000001199 
 
 
Patrick, S., Schumacher, R., Benneyworth, B., Krans, E., McAllister, J., & Davis, M. 
(2013). Neonatal Abstinence Syndrome and Associated Health Care 
Expenditures. Obstetric Anesthesia Digest, 33(2), 86. doi: 




Patrick, S.W., Davis, M. M., Lehmann, C. U., & Cooper, W. O. (2015). Increasing 
incidence and geographic distribution of neonatal abstinence syndrome: United 
States 2009 to 2012. Journal of perinatology: official journal of the California 
Perinatal Association, 35(8), 650–655. doi:10.1038/jp.2015.36 
 
Patrick, S., Faherty, L., Dick, A., Scott, T., Dudley, J., & Stein, B. (2019). Association 
Among County-level Economic Factors, Clinician Supply, Metropolitan or Rural 
Location, and Neonatal Abstinence Syndrome. Obstetric Anesthesia Digest, 39(4), 





Paulozzi, L. J., Mack, K. A., & Hockenberry, J. M. (2014). Variation among states in 
prescribing of opioid pain relievers and benzodiazepines — United States, 




Pozo-Rodríguez, F., Castro-Acosta, A., Alvarez, C. J., López-Campos, J. L., Forte, A., & 
López-Quilez, A. (2015). Determinants of between-hospital variations in outcomes 
for patients admitted with COPD exacerbations: findings from a nationwide clinical 
audit (AUDIPOC) in Spain. International Journal of Clinical Practice, 69(9), 938-
947. doi:10.1111/ijcp.12601 
 
Saloner, B., & Cook, B. L. (2013). Blacks and Hispanics are less likely than Whites to 
complete addiction treatment, largely due to socioeconomic factors. Health 
Affairs, 32(1), 135-145. doi:10.1377/hlthaff.2011.0983. Retrieved from 
https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2011.0983 
 
Stabler, M. E., Long, D. L., Chertok, I. R., Giacobbi, P. R., Pilkerton, C., & Lander, L. R. 
(2016). Neonatal Abstinence Syndrome in West Virginia Substate Regions, 2007-
2013. The Journal of Rural Health, 33(1), 92-101. doi:10.1111/jrh.12174 
 
Stockman, J. (2012). Neonatal abstinence syndrome after methadone or buprenorphine 
exposure. Yearbook of Pediatrics, 2012, 415-416. doi:10.1016/j.yped.2011.04.036 
 
Strahan, A. E., Guy, G. P., Bohm, M., Frey, M., & Ko, J. Y. (2019). Neonatal Abstinence 
Syndrome Incidence and Health Care Costs in the United States, 2016. JAMA 





Thompson, B. (2014). The Use of Statistical Significance Tests in Research. The journal of 
experimental education, 61(4), 361-377. Retrieved from 
https://www.tandfonline.com/doi/abs/10.1080/00220973.1993.10806596    
 
Tolia, V., Patrick, S., Bennett, M., Murthy, K., Sousa, J., Smith, P., … Spitzer, A. (2016). 
Increasing Incidence of the Neonatal Abstinence Syndrome in US Neonatal 
ICUs. Obstetric Anesthesia Digest, 36(1), 38. doi: 
10.1097/01.aoa.0000479516.96285.5d. Retrieved from https://www-nejm-
org.ezproxy.library.unlv.edu/doi/pdf/10.1056/NEJMsa1500439?articleTools=true 
 
Turner, S. D., Gomes, T., Camacho, X., Yao, Z., Guttmann, A., Mamdani, M. M., … 
Dhalla, I. A. (2015). Neonatal opioid withdrawal and antenatal opioid 
prescribing. CMAJ Open, 3(1), E55-E61. doi:10.9778/cmajo.20140065.  
 




U.S. Census Bureau. (2018, January 20). Income data tools. Retrieved from 
https://www.census.gov/topics/income-poverty/income/data.html 
 
Villapiano, N. L., Winkelman, T. N., Kozhimannil, K. B., Davis, M. M., & Patrick, S. W. 
(2017). Rural and Urban Differences in Neonatal Abstinence Syndrome and 
Maternal Opioid Use, 2004 to 2013. JAMA Pediatrics, 171(2), 194. 






Wang, X., Zhu, Y., Dave, C. V., Alrwisan, A. A., Voils, S. A., & Winterstein, A. G. (2017). 
Trends of Neonatal Abstinence Syndrome Epidemic and Maternal Risk Factors in 
Florida. Pharmacotherapy: The Journal of Human Pharmacology and Drug 
Therapy, 37(7), 806-813. doi:10.1002/phar.1947 
 
Warren, M.D., Miller, A.M., Traylor, J., Bauer, A., Patrick, S.W. Centers for Disease 
Control and Prevention (CDC) (2015). Implementation of a Statewide Surveillance 
System for Neonatal Abstinence Syndrome — Tennessee, 2013. MMWR Morbidity 
and mortality weekly report, 64(5):125–128. Retrieved from 
https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6405a4.htm 
 
Whelan, P. J., & Remski, K. (2012). Buprenorphine vs methadone treatment: A review of 
evidence in both developed and developing worlds. Journal of Neurosciences in 
Rural Practice, 03(01), 45-50. doi:10.4103/0976-3147.91934. Retrieved from 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3271614/ 
 
Winkelman, T. N., Villapiano, N., Kozhimannil, K. B., Davis, M. M., & Patrick, S. W. 
(2018). Incidence and Costs of Neonatal Abstinence Syndrome Among Infants with 
Medicaid: 2004–2014. Pediatrics, 141(4), e20173520. doi:10.1542/peds.2017-3520. 
Retrieved from https://pediatrics.aappublications.org/content/141/4/e20173520 
 
Yokell, M. A., Zaller, N. D. & Rich, J. D. (2011). Buprenorphine and 
Buprenorphine/Naloxone Diversion, Misuse, and Illicit Use: An International 






Young, G. J., Flaherty, S., Zepeda, E. D., Singh, S., & Rosenbaum, S. (2019). Impact of 
ACA Medicaid Expansion on Hospitals’ Financial Status. Journal of Healthcare 
Management, 64(2), 91-102. doi:10.1097/jhm-d-17-00177 
 
Zimmermann-Baer, U., Nötzli, U., Rentsch, K., & Bucher, H. U. (2010). Finnegan neonatal 
abstinence scoring system: normal values for first 3 days and weeks 5-6 in non-
addicted infants. Addiction, 105(3), 524-528. doi:10.1111/j.1360-














Doctor of Philosophy (Ph.D.) in Public Health     May 2020 
University of Nevada, Las Vegas 
Dissertation title: Assessing the health and financial burden of neonatal abstinence syndrome 
among all payer in-patient pediatric discharges in Nevada    GPA: 3.99 
 
Master of Public Health        May 2016 
University of Nevada, Las Vegas       GPA: 4.0 
Thesis title: The National Diabetes Prevention Program: an intervention for diabetes risk 
reduction 
  
Bachelor of Dental Surgery (BDS)       1998-2003                                                                                              




• July 2018 – Present 
Adjunct faculty (Online), Southern New Hampshire University 
Courses taught:  Undergraduate Epidemiology, Bio-concepts of Public Health  
• August 2017 - Present  
Part-time instructor, College of Southern Nevada   
Courses taught:  Anatomy and Physiology Laboratory, Biology for non-majors 
• May 2016 - August 2017 
Adjunct faculty, Arizona College School of Nursing (Las Vegas) 
Courses taught: Statistics   
• May 2016   – August 2017  
Adjunct faculty, Arizona College School of Nursing (Las Vegas) 
Courses taught: Anatomy and Physiology lectures    
• August 2016 – August 2017 
Part-time instructor, University of Nevada, Las Vegas 
Courses taught: Epidemiology   
• January 2016 -June 2016 
Research coordinator and data analyst, Nevada Orthopedic & Spine Center  
• Spring 2016 
Tutor for undergraduate students, UNLV 
Courses taught: Biostatistics                          
• Jan 2015 – May 2016 
Data analyst for the National Diabetes Prevention Program at UNLV (Part of MPH 
Thesis project)  
• May 2015 – August 2015 
Data analyst for The Foundation for Positively Kids Inc. (Unpaid Internship)  
• July 2006 – Feb. 2011   




• August 2002- June 2006 
Tutor, Bharati Vidyapeeth Deemed University (India)   
Courses taught: Anatomy & Physiology        
 
 
KNOWLEDGE AND SKILLS  
 
• Statistical analysis experience: SPSS (3+ years); SAS (2+ years) 
• Proficient in advanced statistical methods (multilevel modelling, bootstrap, multivariate 
analysis) 
• Proficient in teaching at the college level (experience 3+ years in United States; 4+ years 
in India) 
• Data analysis (3+ years) 
• Other computer skills: SQL, MS Access, MS Excel, MS PowerPoint, MS Word, Adobe 
Forms, GitHub, JIRA tool, Version One 
• Expert user of Learning Management Systems (Canvas, Brightspace and Web-campus) 
• Study designing skills (1 year) 
• Drafting of IRB protocols (1 year) 
• Ability to collect data from Electronic Health Records 




• Certification in R-Programming through Coursera 
• CITI Certification: Human Research Subjects Protection 
• Certification in conducting systematic reviews and metanalysis through Coursera 
• Certification in understanding clinical research: behind the statistics through Coursera 
• Certification in COVID-19 contact tracing through Coursera  
• Graduate Research Certification  
• Graduate Mentorship Certificate  





• American Statistical Association 
• Nevada Public Health Association 




GPSA representative [School of Public Health], UNLV, Las Vegas  2017-present 
GPSA Emergency Scholarship Committee, UNLV, Las Vegas  2017-present 
Graduate Awards’ Committee, UNLV, Las Vegas    2017-2018 
Academic Technology Committee, Arizona College School of Nursing 2016-2017 
Science Committee, Arizona College School of Nursing   2016-2017 













• Spring, 2019 
Served as a judge in the Undergraduate Research Symposium   
• November 2015 
Drafting a research protocol for the program (initiated by Positively Kids Inc.) targeting  
drug exposed infants in Nevada 
• Spring, 2015 
Voluntarily lectured in Chronic Epidemiology Course 
• August 2013 
Participation in Children Immunization Program, Fort Worth, Texas 
• January 2009 - July 2010 
Supervisor in AIDS Awareness Campaign (India)   
• April 2006 - Dec.2009 






Batra, K., Abdulla, F., and Haboush-Deloye, A. Assessment of the Average Length of Stay 
of Premature Babies and Calculation of Associated Cost of Stay. March of Dimes 
Prematurity Prevention Conference. November 17-18, 2015. Arlington, Virginia.   
 
Batra, K., Mercado, G., and Cruz, P. Babies Born Addicted: A Comprehensive Literature 
Review Investigating the Risk of Neonatal Abstinence Syndrome (NAS). Graduate 
Professional Student Association (GPSA) Research Forum. February 29, 2020. University of 
Nevada, Las Vegas. 
 
Mercado, G., Batra, K., and Cruz, P. Babies Born Too Soon: Psychosocial Factors That 
Influence Preterm Births. Undergraduate Research Symposium. May 1, 2020. University of 




Batra, K., Moonie, S., Dodge-Francis, C., and Shan, G. The National Diabetes Prevention 
Program: an intervention for diabetes risk reduction. Oral presentation at the Nevada Public 






Batra, K., & Pharr, J. The Maternal Psychosocial Factors Associated with Preterm Birth. 
Oral presentation at the Nevada Public Health Association Annual Conference. September 
28-29, 2017. Reno, Nevada. 
 
Batra, K., & Pharr, J. The Maternal Physical and Pregnancy Related Factors Associated with 
Preterm Birth. Oral presentation at the Nevada Public Health Association Annual 
Conference. September 28-29, 2017. Reno, Nevada. 
 
Batra, K., & Cruz, P. Factors Increasing the Risk of Preterm Birth Resulting from Infertility 
Treatments: A Systematic Review. Oral presentation at the Nevada Public Health Association 
Annual Conference. September 26-27, 2018. Las Vegas, Nevada. 
 
 
AWARDS & ACHIEVEMENTS 
 
              
The Public & Community Health Benefit Scholarship, SPH, UNLV (1,000) 
April 2016 
 
The Patricia Sastaunik Scholarship, Graduate College, UNLV ($2,500)                        
May 2016 
           
The UNLV James F. Adams/GPSA Scholarship ($1,000)       
May 2016                                                   
       
The UNLV Graduate Access Childcare Scholarship ($3,000)     
May 2016 
 
Best Faculty of the Year Award, Arizona College, School of Nursing, Las Vegas, Nevada 
December 2016  
 
The Patricia Sastaunik Scholarship, Graduate College, UNLV ($2,500)                   
May 2017 
 
The UNLV Graduate Access Childcare Scholarship ($2,250)     
May 2017 
 
The Patricia Sastaunik Scholarship, Graduate College, UNLV ($2,500) 
May 2018 
 
The Patricia Sastaunik Scholarship, Graduate College, UNLV ($2,500)                                                           
June 2019 
 
The Summer Session Scholarship, UNLV ($2,000)                                                                                         
May 2019 
 







The Grad Rebel Finishing Fellowship ($12,000)       
January 2020 
 
Recipient of Graduate College Medallion 
Spring 2020 
